Annual Statements Open main menu

AXON ENTERPRISE, INC. - Quarter Report: 2014 September (Form 10-Q)

Form 10-Q
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 10-Q

 

 

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014

or

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission File Number 001-16391

 

 

TASER International, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   86-0741227

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

17800 North 85th Street,

Scottsdale, Arizona

  85255
(Address of principal executive offices)   (Zip Code)

(480) 991-0797

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   ¨    Accelerated filer   x
Non-accelerated filer   ¨  (Do not check if smaller reporting company)    Smaller reporting company   ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

There were 52,516,777 shares of the issuer’s common stock, par value $0.00001 per share, outstanding as of October 31, 2014.

 

 

 


Table of Contents

TASER INTERNATIONAL, INC.

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2014

TABLE OF CONTENTS

 

     Page  

PART I — FINANCIAL INFORMATION

  

Item 1. Financial Statements

  

Condensed Consolidated Balance Sheets as of September 30, 2014 (Unaudited) and December 31, 2013

     3   

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended September 30, 2014 and 2013

     4   

Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September  30, 2014 and 2013

     5   

Notes to Unaudited Condensed Consolidated Financial Statements

     6   

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

     21   

Item 3. Quantitative and Qualitative Disclosures About Market Risk

     34   

Item 4. Controls and Procedures

     35   

PART II — OTHER INFORMATION

  

Item 1. Legal Proceedings

     35   

Item 1A. Risk Factors

     35   

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

     35   

Item 3. Defaults Upon Senior Securities

     36   

Item 4. Mine Safety Disclosures

     36   

Item 5. Other Information

     36   

Item 6. Exhibits

     37   

SIGNATURES

     38   

INDEX TO EXHIBITS

     39   

 

2


Table of Contents

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

TASER INTERNATIONAL, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

 

     September 30, 2014     December 31, 2013  
     (Unaudited)        
ASSETS   

Current Assets:

    

Cash and cash equivalents

   $ 38,615      $ 42,271   

Short-term investments

     28,983        9,101   

Accounts and notes receivable, net of allowance of $253 and $200 as of September 30, 2014 and December 31, 2013, respectively

     27,099        22,488   

Inventory, net

     16,128        11,109   

Prepaid expenses and other current assets

     5,210        5,397   

Deferred income tax assets, net

     7,164        7,101   
  

 

 

   

 

 

 

Total current assets

     123,199        97,467   

Property and equipment, net of accumulated depreciation of $33,046 and $31,378 as of September 30, 2014 and December 31, 2014, respectively

     17,848        19,043   

Deferred income tax assets, net

     9,603        13,679   

Intangible assets, net

     3,107        3,317   

Goodwill

     2,206        2,235   

Long-term investments

     6,411        12,023   

Other assets

     1,766        618   
  

 

 

   

 

 

 

Total assets

   $ 164,140      $ 148,382   
  

 

 

   

 

 

 
LIABILITIES AND STOCKHOLDERS’ EQUITY   

Current Liabilities:

    

Accounts payable

   $ 6,483      $ 6,221   

Accrued liabilities

     6,853        8,840   

Current portion of deferred revenue

     10,033        6,878   

Customer deposits

     369        1,154   

Current portion of capital lease payable

     38        36   
  

 

 

   

 

 

 

Total current liabilities

     23,776        23,129   

Deferred revenue, net of current portion

     19,966        13,341   

Liability for unrecognized tax benefits

     1,409        3,122   

Other long-term liabilities

     908        376   

Long-term portion of capital lease payable

     39        67   
  

 

 

   

 

 

 

Total liabilities

     46,098        40,035   
  

 

 

   

 

 

 

Commitments and Contingencies (Note 10)

    

Stockholders’ Equity

    

Preferred stock, $0.00001 par value per share; 25 million shares authorized; no shares issued at September 30, 2014 and December 31, 2013

     —          —     

Common stock, $0.00001 par value per share; 200 million shares authorized; 52,516,219 and 52,725,247 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively

     1        1   

Additional paid-in capital

     156,729        139,424   

Treasury stock at cost, 18,139,958 and 16,412,755 shares at September 30, 2014 and December 31, 2013, respectively

     (114,645     (92,203

Retained earnings

     75,959        61,127   

Accumulated other comprehensive loss

     (2     (2
  

 

 

   

 

 

 

Total stockholders’ equity

     118,042        108,347   
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 164,140      $ 148,382   
  

 

 

   

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

3


Table of Contents

TASER INTERNATIONAL, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(in thousands, except per share data)

 

     Three Months Ended September 30,      Nine Months Ended September 30,  
     2014     2013      2014     2013  

Net sales

   $ 44,349      $ 35,197       $ 117,709      $ 97,806   

Cost of products sold and services delivered

     15,636        13,101         43,574        37,517   
  

 

 

   

 

 

    

 

 

   

 

 

 

Gross margin

     28,713        22,096         74,135        60,289   

Sales, general and administrative expenses

     12,441        12,776         39,734        34,898   

Research and development expenses

     3,759        2,439         10,820        6,444   
  

 

 

   

 

 

    

 

 

   

 

 

 

Income from operations

     12,513        6,881         23,581        18,947   

Interest and other income (expense), net

     (160     35         (88     31   
  

 

 

   

 

 

    

 

 

   

 

 

 

Income before provision for income taxes

     12,353        6,916         23,493        18,978   

Provision for income taxes

     4,795        1,802         8,661        6,109   
  

 

 

   

 

 

    

 

 

   

 

 

 

Net income

   $ 7,558      $ 5,114       $ 14,832      $ 12,869   
  

 

 

   

 

 

    

 

 

   

 

 

 

Income per common and common equivalent shares

         

Basic

   $ 0.14      $ 0.10       $ 0.28      $ 0.25   

Diluted

   $ 0.14      $ 0.10       $ 0.27      $ 0.24   

Weighted average number of common and common equivalent shares outstanding

         

Basic

     52,475        51,342         53,013        51,727   

Diluted

     53,821        53,321         54,550        53,644   
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME   

Net income

   $ 7,558      $ 5,114       $ 14,832      $ 12,869   

Foreign currency translation adjustments

     (15     92         —          29   
  

 

 

   

 

 

    

 

 

   

 

 

 

Comprehensive income

   $ 7,543      $ 5,206       $ 14,832      $ 12,898   
  

 

 

   

 

 

    

 

 

   

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4


Table of Contents

TASER INTERNATIONAL, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

 

     Nine Months Ended September 30,  
     2014     2013  

Cash Flows from Operating Activities:

    

Net income

   $ 14,832      $ 12,869   

Adjustments to reconcile net income to net cash provided by operating activities:

    

Depreciation and amortization

     3,368        4,036   

Loss (gain) on disposal of property and equipment, net

     17        (29

Loss on write-down / disposal of intangible assets, net

     211        113   

Bond premium amortization

     675        174   

Provision for doubtful accounts

     143        2   

Provision for excess and obsolete inventory

     20        279   

Provision for warranty

     517        644   

Stock-based compensation expense

     4,121        2,906   

Deferred income taxes

     9,862        5,212   

Unrecognized tax benefits

     (1,713     172   

Excess tax benefit from stock-based compensation

     (5,849     (4,058

Change in assets and liabilities:

    

Accounts and notes receivable

     (4,754     (1,994

Inventory

     (5,039     (1,575

Prepaid expenses and other assets

     (1,063     (2,243

Accounts payable and accrued liabilities

     (1,705     (496

Deferred revenue

     9,780        6,497   

Customer deposits

     (785     578   
  

 

 

   

 

 

 

Net cash provided by operating activities

     22,638        23,087   
  

 

 

   

 

 

 

Cash Flows from Investing Activities:

    

Purchases of investments

     (23,613     (18,450

Proceeds from call / maturity of investments

     8,668        6,625   

Purchases of property and equipment

     (2,066     (1,174

Proceeds from disposal of fixed assets

     10        34   

Purchases of intangible assets

     (125     (271
  

 

 

   

 

 

 

Net cash used in investing activities

     (17,126     (13,236
  

 

 

   

 

 

 

Cash Flows from Financing Activities:

    

Repurchase of common stock

     (22,442     (25,000

Proceeds from options exercised

     8,597        10,219   

Payroll tax payments for net-settled stock awards

     (1,262     (221

Excess tax benefit from stock-based compensation

     5,849        4,058   

Payments on capital lease obligation

     (26     (25
  

 

 

   

 

 

 

Net cash used in financing activities

     (9,284     (10,969
  

 

 

   

 

 

 

Effect of exchange rate change on cash and cash equivalents

     116        (3
  

 

 

   

 

 

 

Net decrease in cash and cash equivalents

     (3,656     (1,121

Cash and cash equivalents, beginning of period

     42,271        36,127   
  

 

 

   

 

 

 

Cash and cash equivalents, end of period

   $ 38,615      $ 35,006   
  

 

 

   

 

 

 

Supplemental Disclosure:

    

Cash paid for income taxes, net

   $ 403      $ 2,427   

Non-Cash Transactions:

    

Property and equipment purchases in accounts payable

   $ 158      $ 59   

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

5


Table of Contents

TASER INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Organization and Summary of Significant Accounting Policies

TASER International, Inc. (the “Company” or “TASER”) is a developer and manufacturer of advanced conducted electrical weapons (“CEWs”) designed for use in law enforcement, federal, military, corrections, private security and personal defense. In addition, the Company has developed full technology solutions for the capture, storage and management of video/audio evidence as well as other tactical capabilities for use in law enforcement. The Company sells its products worldwide through its direct sales force, distribution partners, online store and third-party resellers. The Company was incorporated in Arizona in September 1993, and reincorporated in Delaware in January 2001. The Company’s corporate headquarters and manufacturing facilities are located in Scottsdale, Arizona. The Company’s software development business unit facilities are located in Seattle, Washington.

The accompanying condensed consolidated financial statements include the accounts of the Company, and its wholly owned subsidiaries, including TASER International Europe SE (“TASER Europe”). TASER Europe was established in 2009 to facilitate sales and provide customer service to our customers in the European region. All material intercompany accounts, transactions, and profits have been eliminated in consolidation.

a. Basis of presentation, preparation and use of estimates

These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information related to the Company’s organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in the Company’s annual consolidated financial statements for the year ended December 31, 2013, as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments, consisting only of normal recurring adjustments, necessary to fairly state the Company’s financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with the Company’s Form 10-K for the year ended December 31, 2013. The results of operations for the three and nine months ended September 30, 2014 and 2013 are not necessarily indicative of the results to be expected for the full year (or any other period). Significant estimates and assumptions in these unaudited condensed consolidated financial statements include:

 

    product warranty reserves,

 

    inventory valuation reserves,

 

    revenue recognition allocated in multiple-deliverable arrangements,

 

    the carrying value of long-lived assets including property and equipment, goodwill and other intangible assets,

 

    recognition, measurement and valuation of current and deferred income taxes,

 

    fair value of stock awards issued, the estimated vesting period for performance-based stock awards and forfeiture rates, and

 

    recognition and measurement of contingencies and accrued litigation expense.

Actual results could differ materially from these estimates.

b. Segment information

The Company is comprised of two reportable segments: the manufacture and sale of CEWs, accessories and other related products and services (the “TASER Weapons” segment); and the video business which includes the TASER Cam, AXON video products and EVIDENCE.com (the “EVIDENCE.com & Video” segment). Reportable segments are determined based on discrete financial information reviewed by the Company’s Chief Executive Officer who is the Chief Operating Decision Maker (the “CODM”) for the Company. The Company organizes and reviews operations based on products and services, and currently, there are no operating segments that are aggregated. The Company performs an annual analysis of its reportable segments. Additional information related to the Company’s segments is summarized in Note 13.

 

6


Table of Contents

TASER INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

c. Geographic information and major customers

For the three and nine months ended September 30, 2014 and 2013, net sales by geographic area were as follows (dollars in thousands):

 

     Three Months Ended September 30,     Nine Months Ended September 30,  
     2014     2013     2014     2013  

United States

   $ 37,605         84.8   $ 31,483         89.4   $ 95,336         81.0   $ 86,036         88.0

Other Countries

     6,744         15.2        3,714         10.6        22,373         19.0        11,770         12.0   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Total

   $ 44,349         100.0   $ 35,197         100.0   $ 117,709         100.0   $ 97,806         100.0
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Sales to customers outside of the United States are typically denominated in U.S. dollars and are attributed to each country based on the shipping address of the distributor or customer. For the three and nine months ended September 30, 2014 and 2013, no individual country outside of the United States represented greater than 10% of total net sales. Sales in the international market generally are larger and occur more intermittently than in the domestic market due to the profile of the Company’s customers.

For the three months ended September 30, 2014, one customer represented approximately 11.0% of total net sales. For the nine months ended September 30, 2014, no customers represented more than 10% of total net sales. In the three and nine months ended September 30, 2013, one distributor represented approximately 12.2% and 12.1% of total net sales, respectively. At September 30, 2014, the Company had receivables from two customers comprising approximately 27.2% of the aggregate accounts receivable balance, and at December 31, 2013, the Company had receivables from one customer comprising approximately 17.4% of the aggregate accounts receivable balance.

d. Income per common share

Basic income per common share is computed by dividing net income by the weighted average number of common shares outstanding during the periods presented. Diluted income per share is calculated based on the weighted average number of common shares outstanding for the period plus the dilutive effect of stock options and restricted stock units using the treasury stock method. The calculation of the weighted average number of shares outstanding and income per share are as follows (in thousands, except per share data):

 

     Three Months Ended September 30,      Nine Months Ended September 30,  
     2014      2013      2014      2013  

Numerator for basic and diluted earnings per share:

           

Net income

   $ 7,558       $ 5,114       $ 14,832       $ 12,869   
  

 

 

    

 

 

    

 

 

    

 

 

 

Denominator:

           

Weighted average shares outstanding — basic

     52,475         51,342         53,013         51,727   

Dilutive effect of stock-based awards

     1,346         1,979         1,537         1,917   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted weighted average shares outstanding

     53,821         53,321         54,550         53,644   
  

 

 

    

 

 

    

 

 

    

 

 

 

Anti-dilutive stock-based awards excluded

     336         565         328         898   
  

 

 

    

 

 

    

 

 

    

 

 

 

Net income per common share:

           

Basic

   $ 0.14       $ 0.10       $ 0.28       $ 0.25   

Diluted

   $ 0.14       $ 0.10       $ 0.27       $ 0.24   

e. Revenue recognition

The Company derives revenue from two primary sources: (1) the sale of physical products, including CEWs, AXON cameras, corresponding extended warranties, and related accessories such as cartridges and batteries, and (2) subscription to EVIDENCE.com, the Company’s digital evidence management Software-as-a-Solution (“SaaS”) (including data storage fees and other ancillary services), which includes varying levels of support. To a lesser extent, the Company also recognizes training and other revenue. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, title has transferred, the price is fixed and collectability is reasonably assured. Extended warranty revenue, SaaS revenue and related data storage revenue are recognized ratably over the term of the contract beginning on the commencement date of each contract.

 

7


Table of Contents

TASER INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

Revenue arrangements with multiple deliverables are divided into separate units and revenue is allocated using the relative selling price method based upon vendor-specific objective evidence of selling price, or third-party evidence of selling price if vendor-specific objective evidence does not exist. If neither vendor-specific objective evidence nor third-party evidence exists, management uses its best estimate of selling price.

The Company offers customers the right to purchase extended warranties that include additional services and coverage beyond the limited warranty for certain products. Revenue for extended warranty purchases is deferred at the time of sale and recognized over the warranty period commencing on the date of sale. Extended warranties range from one to five years.

EVIDENCE.com and AXON cameras are sold separately, but in most instances are purchased together. In these instances, customers typically purchase and pay for the equipment and one year of EVIDENCE.com in advance. Additional years of service are generally billed annually over a specified service term, which has typically ranged from one to five years. AXON equipment has stand-alone value and represents a deliverable that is provided to the customer at the time of sale, while EVIDENCE.com services are provided over the specified term of the contract. The Company recognizes revenue for the AXON equipment at the time of the sale consistent with the discussion of multiple deliverable arrangements above. Revenue for EVIDENCE.com is deferred at the time of the sale and recognized over the service period. In certain circumstances, not all requirements are met for the recognition of revenue relative to equipment sold in conjunction with EVIDENCE.com at the time the equipment is provided to customers. In such circumstances, based on limitations associated with the arrangement consideration, the revenue may be recognized ratably over the specified term of the contract, or when all conditions for revenue recognition are met, if sooner.

The Company offers the TASER Assurance Program (“TAP”) whereby a customer purchasing a product and joining the program will have the right to trade-in the original product for a new product of the same or like model in the future. Upon joining TAP, customers also receive an extended warranty for the initial products purchased and spare inventory. Under this program the customer generally pays additional annual installments over the contract period, generally three to five years. The Company records consideration received related to the future purchase as deferred revenue until all revenue recognition criteria are met, which is generally at the end of the contract period when the product is delivered.

Sales tax collected on sales is netted against government remittances and thus, recorded on a net basis. Training revenue is recorded as the service is provided.

Deferred revenue consists of billings and/or payments received in advance related to products and services for which the criteria for revenue recognition have not yet been met. Deferred revenue that will be recognized during the succeeding twelve month period is recorded as current deferred revenue and the remaining portion is recorded as long-term. Deferred revenue does not include future revenue from multi-year contracts for which no invoice has yet been created. Generally, customers are billed in annual installments. See Note 5 for further discussion of the Company’s deferred revenue.

Sales are typically made on credit and the Company generally does not require collateral. Management performs ongoing credit evaluations of its customers’ financial condition and maintains an allowance for estimated potential losses. Uncollectable accounts are charged to expense when deemed uncollectible, and accounts and notes receivable are presented net of an allowance for doubtful accounts. This allowance represents management’s best estimate and is based on their judgment after considering a number of factors, including third-party credit reports, actual payment history, cash discounts, customer-specific financial information and broader market and economic trends and conditions.

The Company may, from time to time, enter into agreements with its customers to finance a customer’s purchases with a note receivable that may range in terms up to five years. Sales are recorded at the fair value of the note, which is generally sold and assigned to a third-party financing company. The terms of the assignments are such that the Company expects to receive payment within 30 days of the original sale. The assignments are non-recourse and the Company has no obligations or continuing involvement with these notes receivable. Prior to entering into an assignment, the Company evaluates the credit quality and financial condition of the third-party financing company. As of September 30, 2014 there was $0.8 million in accounts and notes receivable related to such arrangements. No such balances were recorded at December 31, 2013. The Company did not record any interest income on notes receivable due to the minimal holding periods, nor has the Company recognized gains or losses upon the assignment of these notes.

 

8


Table of Contents

TASER INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

f. Warranty costs

The Company warranties its CEWs, StrikeLight, AXON cameras and E-Docks from manufacturing defects on a limited basis for a period of one year after purchase and, thereafter, will replace any defective unit for a fee. Estimated costs for the standard warranty are charged to cost of products sold and services delivered when revenue is recorded for the related product. Future warranty costs are estimated based on historical data related to returns and warranty costs on a quarterly basis and this rate is applied to current product sales. Historically, reserve amounts have been increased if management becomes aware of a component failure that could result in larger than anticipated returns from customers. The accrued warranty liability is reviewed quarterly to evaluate whether it sufficiently reflects the remaining warranty obligations based on the anticipated expenditures over the balance of the warranty obligation period, and adjustments are made when actual warranty claim experience differs from estimates. Costs related to extended warranties are charged to cost of products sold and services delivered when incurred.

The reserve for warranty returns is included in accrued liabilities on the condensed consolidated balance sheets. The Company recognized additional warranty expense during the first nine months of 2014 due to a change in estimate regarding the Company’s first generation E-Dock as a result of an updated version launched in the first quarter. The Company also recognized additional warranty expense during the nine months ended September 30, 2013 due to a change in estimate for the AXON flex and X26P CEWs based on the analysis of return data for their first year of sales. Changes in the Company’s estimated product warranty liabilities are as follows (in thousands):

 

     Nine Months Ended September 30,  
     2014     2013  

Balance, beginning of period,

   $ 955      $ 484   

Utilization of accrual

     (646     (420

Warranty expense

     517        644   
  

 

 

   

 

 

 

Balance, end of period,

   $ 826      $ 708   
  

 

 

   

 

 

 

g. Fair value of financial instruments

The Company uses the fair value framework, which prioritizes the inputs to valuation techniques for measuring financial assets and liabilities measured on a recurring basis and for non-financial assets and liabilities when these items are re-measured. Fair value is considered to be the exchange price in an orderly transaction between market participants, to sell an asset or transfer a liability at the measurement date. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

 

    Level 1 – Valuation techniques in which all significant inputs are unadjusted quoted prices from active markets for assets or liabilities that are identical to the assets or liabilities being measured.

 

    Level 2 – Valuation techniques in which significant inputs include quoted prices from active markets for assets or liabilities that are similar to the assets or liabilities being measured and/or quoted prices for assets or liabilities that are identical or similar to the assets or liabilities being measured from markets that are not active. Also, model-derived valuations in which all significant inputs and significant value drivers are observable in active markets are Level 2 valuation techniques.

 

    Level 3 – Valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Unobservable inputs are valuation technique inputs that reflect the Company’s own assumptions about the assumptions that market participants would use in pricing an asset or liability.

The Company has cash equivalents and investments that at September 30, 2014 and December 31, 2013 were comprised of money market funds, state and municipal obligations, corporate bonds, and certificates of deposits. See additional disclosure regarding the fair value of the Company’s cash equivalents and investments in Note 2. Included in the balance of Other assets as of September 30, 2014 is $1.0 million related to corporate-owned life insurance policies which are used to fund the Company’s deferred compensation plan. The Company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the policy issuer, a Level 2 valuation technique.

The Company’s financial instruments also include accounts and notes receivable, accounts payable and accrued liabilities. Due to the short-term nature of these instruments, their fair values approximate their carrying values on the balance sheet.

 

9


Table of Contents

TASER INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

h. Impairment of Long-Lived Assets

Management evaluates whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets may warrant revision or that the remaining balance of these assets may not be recoverable. Such circumstances could include, but are not limited to, a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way products are branded and marketed. In performing the review for recoverability, management estimates the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of the impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair value computed using discounted cash flows. No impairment losses were recorded in the three or nine months ended September 30, 2014 and 2013.

i. Recently issued accounting guidance

In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification Topic No. 718, “Compensation—Stock Compensation” (“ASC 718”), as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (i) prospectively to all awards granted or modified after the effective date; or (ii) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company is currently evaluating the potential impact of the adoption of this guidance on its consolidated financial statements, however does not expect there to be a material impact at this time.

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). The core principle of ASU 2014-09 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, ASU 2014-09 provides for the following steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification Topic No. 605, “Revenue Recognition,” most industry-specific guidance throughout the industry topics of the Accounting Standards Codification, and some cost guidance related to construction-type and production-type contracts. ASU 2014-09 is effective for public entities for annual periods and interim periods within those annual periods beginning after December 15, 2016. Early adoption is not permitted. Companies may use either a full retrospective or a modified retrospective approach to adopt ASU 2014-09. The Company is currently evaluating the potential impact of the adoption of this guidance on its consolidated financial statements.

In July 2013, the FASB issued ASU No. 2013-11 to standardize the balance sheet presentation of unrecognized tax benefits. This update applies to all entities that have unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists at the reporting date. The new guidance was effective for fiscal years beginning after December 15, 2013. The adoption of this guidance resulted in an immaterial reclassification on the Company’s consolidated balance sheet.

j. Reclassification of Prior Year Presentation

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.

 

10


Table of Contents

TASER INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

2. Cash, cash equivalents, and investments

The following tables summarizes the Company’s cash, cash equivalents and held-to-maturity investments at September 30, 2014 and December 31, 2013 (in thousands):

 

     As of September 30, 2014  
     Amortized
Cost
     Gross
Unrealized
Gains
     Gross
Unrealized
Losses
    Fair
Value
     Cash and
Cash
Equivalents
     Short-Term
Investments
     Long-Term
Investments
 

Cash

   $ 36,392       $ —         $ —        $ 36,392       $ 36,392       $ —         $ —     

Level 1:

                   

Money market funds

     2,223         —           —          2,223         2,223         —           —     

Corporate bonds

     15,455         3         (20     15,438         —           12,811         2,644   
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

    

 

 

    

 

 

 

Subtotal

     17,678         3         (20     17,661         2,223         12,811         2,644   
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

    

 

 

    

 

 

 

Level 2:

                   

State and municipal obligations

     17,466         21         —          17,487         —           14,689         2,777   

Certificates of deposit

     2,473         —           —          2,473         —           1,483         990   
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

    

 

 

    

 

 

 

Subtotal

     19,939         21         —          19,960         —           16,172         3,767   
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 74,009       $ 24       $ (20   $ 74,013       $ 38,615       $ 28,983       $ 6,411   
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

    

 

 

    

 

 

 
     As of December 31, 2013  
     Amortized
Cost
     Gross
Unrealized
Gains
     Gross
Unrealized
Losses
    Fair
Value
     Cash and
Cash
Equivalents
     Short-Term
Investments
     Long-Term
Investments
 

Cash

   $ 37,196       $ —         $ —        $ 37,196       $ 37,196       $ —         $ —     

Level 1:

                   

Money market funds

     5,030         —           —          5,030         5,030         —           —     

Corporate bonds

     7,743         3         (14     7,732         —           1,102         6,641   
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

    

 

 

    

 

 

 

Subtotal

     12,773         3         (14     12,762         5,030         1,102         6,641   
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

    

 

 

    

 

 

 

Level 2:

                   

State and municipal obligations

     10,807         14         —          10,821         45         5,626         5,136   

Certificates of deposit

     2,619         —           —          2,619         —           2,373         246   
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

    

 

 

    

 

 

 

Subtotal

     13,426         14         —          13,440         45         7,999         5,382   
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 63,395       $ 17       $ (14   $ 63,398       $ 42,271       $ 9,101       $ 12,023   
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

    

 

 

    

 

 

 

The Company believes the unrealized losses on the Company’s investments are due to interest rate fluctuations. As these investments are either short-term in nature, are expected to be redeemed at par value and/or because the Company has the ability and intent to hold these investments to maturity, the Company does not consider these investments to be other than temporarily impaired at September 30, 2014. None of Company’s investments have been in an unrealized loss position for more than one year.

The following table summarizes the amortized cost and fair value of the short-term and long-term investments held by the Company at September 30, 2014 by contractual maturity (in thousands):

 

     Amortized Cost      Fair Value  

Due in less than one year

   $ 28,983       $ 28,989   

Due after one year, through two years

     6,163         6,167   

Due after two years

     248         242   
  

 

 

    

 

 

 

Total short-term and long-term investments

   $ 35,394       $ 35,398   
  

 

 

    

 

 

 

 

11


Table of Contents

TASER INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

3. Inventory

Inventories are stated at the lower of cost or market. Cost is determined using the weighted average cost of raw materials, which approximates the first-in, first-out (“FIFO”) method, and includes allocations of manufacturing labor and overhead. Provisions are made to reduce potentially excess, obsolete or slow-moving inventories to their net realizable value. Inventories as of September 30, 2014 and December 31, 2013, consisted of the following (in thousands):

 

     September 30,     December 31,  
     2014     2013  

Raw materials

   $ 10,697      $ 7,376   

Work-in-process

     134        44   

Finished goods

     6,043        4,688   

Reserve for excess and obsolete inventory

     (746     (999
  

 

 

   

 

 

 

Total inventory

   $ 16,128      $ 11,109   
  

 

 

   

 

 

 

4. Goodwill and Intangible assets

In the fourth quarter of 2013, the Company recorded goodwill related to the acquisition of Familiar, Inc. (“Familiar”), which was calculated as the excess of the purchase price over the fair value of the identifiable tangible and intangible assets. The balance of goodwill at both September 30, 2014 and December 31, 2013 was $2.2 million.

Other intangible assets consisted of the following at September 30, 2014 and December 31, 2013 (in thousands):

 

          September 30, 2014      December 31, 2013  
     Useful Life    Gross
Carrying
Amount
     Accumulated
Amortization
    Net Carrying
Amount
     Gross
Carrying
Amount
     Accumulated
Amortization
    Net Carrying
Amount
 

Amortized:

                  

Domain names

   5 Years    $ 125       $ (111   $ 14       $ 125       $ (102   $ 23   

Issued patents

   4 to 15 Years      1,735         (524     1,211         1,529         (441     1,088   

Issued trademarks

   9 to 11 Years      558         (191     367         437         (147     290   
     

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

Total amortized

        2,418         (826     1,592         2,091         (690     1,401   
     

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

Not amortized:

                  

TASER trademark

        900           900         900           900   

Patents and trademarks pending

        615           615         1,016           1,016   
     

 

 

      

 

 

    

 

 

      

 

 

 

Total not amortized

        1,515           1,515         1,916           1,916   
     

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

Total intangible assets

      $ 3,933       $ (826   $ 3,107       $ 4,007       $ (690   $ 3,317   
     

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

Amortization expense relative to intangible assets for the three months ended September 30, 2014 and 2013 was approximately $71,000 and $39,000, respectively. Amortization expense relative to intangible assets for the nine months ended September 30, 2014 and 2013 was approximately $153,000 and $115,000, respectively. Estimated amortization expense of intangible assets for the remaining three months of 2014, the next five years ended December 31, and thereafter is as follows (in thousands):

 

2014 (remaining three months)

   $ 46   

2015

     178   

2016

     171   

2017

     167   

2018

     157   

2019

     147   

Thereafter

     726   
  

 

 

 

Total

   $ 1,592   
  

 

 

 

 

12


Table of Contents

TASER INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

5. Deferred Revenue

Deferred revenue consisted of the following at September 30, 2014 and December 31, 2013 (in thousands):

 

     September 30,      December 31,  
     2014      2013  

Warranty

   $ 20,275       $ 15,889   

EVIDENCE.com

     6,864         4,026   

TASER Assurance Program

     2,771         138   

Other

     89         166   
  

 

 

    

 

 

 

Total deferred revenue

     29,999         20,219   

Total current portion of deferred revenue

     10,033         6,878   
  

 

 

    

 

 

 

Total long-term portion of deferred revenue

   $ 19,966       $ 13,341   
  

 

 

    

 

 

 

Included in the current portion of deferred revenue at September 30, 2014 is approximately $3.3 million related to EVIDENCE.com and $6.3 million related to warranties, and $0.3 million related to the TASER Assurance Program. TASER Assurance Program deferred revenue includes the value of the price-lock for a future purchase as well as the guarantee of the product, both of which will be recognized upon delivery of the product at the end of the contract period. For more information relating to the Company’s revenue recognition policies please refer to Note 1(e).

6. Accrued liabilities

Accrued liabilities consisted of the following at September 30, 2014 and December 31, 2013 (in thousands):

 

     September 30,      December 31,  
     2014      2013  

Accrued salaries and benefits

   $ 3,070       $ 2,328   

Accrued judgments and settlements

     330         3,350   

Accrued professional fees

     368         286   

Accrued warranty expense

     826         955   

Accrued income and other taxes

     349         437   

Other accrued expenses

     1,910         1,484   
  

 

 

    

 

 

 

Accrued liabilities

   $ 6,853       $ 8,840   
  

 

 

    

 

 

 

The judgment in the case AA & SABA Consultant, Inc. vs. TASER of $4.5 million was paid in the second quarter of 2014, of which $3.3 million was accrued for at December 31, 2013, which reduced accrued judgments and settlements to $0.3 million as of September 30, 2014 (see Note 10).

7. Income taxes

Deferred Tax Assets

Net deferred income tax assets at September 30, 2014, include capitalized research and development costs, research and development tax credits, non-qualified stock-based compensation expense, deferred warranty revenue, warranty and inventory reserves, accrued vacation, and other items, partially offset by accelerated depreciation expense. The Company’s total current and long-term net deferred tax assets at September 30, 2014 are $16.8 million.

 

13


Table of Contents

TASER INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

In preparing the Company’s condensed consolidated financial statements, management assesses the likelihood that its deferred tax assets will be realized from future taxable income. In evaluating the Company’s ability to recover its deferred income tax assets, management considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction by jurisdiction basis. A valuation allowance is established if it is determined that it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Management exercises significant judgment in determining its provisions for income taxes, its deferred tax assets and liabilities, and its future taxable income for purposes of assessing its ability to utilize any future tax benefit from its deferred tax assets. Although management believes that its tax estimates are reasonable, the ultimate tax determination involves significant judgments that could become subject to audit by tax authorities in the ordinary course of business, as well as the generation of sufficient future taxable income. Management has determined that it is more likely than not that future sales and profitability will allow for the utilization of the deferred tax assets; however, the deferred tax asset could be reduced or a valuation allowance could be recorded in the near-term if estimates of future taxable income during the carry forward period change.

The Company has completed research and development (“R&D”) tax credit studies which identified approximately $10.4 million in tax credits for federal, Arizona and California income tax purposes related to the 2003 through 2014 tax years. Management has made the determination that it is more likely than not that the full benefit of the R&D tax credit will not be sustained on examination and recorded a liability for unrecognized tax benefits of $3.2 million as of September 30, 2014. In addition, management accrued approximately $0.1 million for estimated uncertain tax positions related to certain state income tax liabilities. As of September 30, 2014 management does not expect the amount of the unrecognized tax benefit liability to increase or decrease significantly within the next 12 months. Should the total unrecognized tax benefit of $3.3 million be recognized, the Company’s effective tax rate would be favorably impacted. Approximately $1.9 million of the unrecognized tax benefit associated with research and development credits has been netted against the research and development credit deferred tax asset.

Effective Tax Rate

The Company’s overall effective tax rate for the nine months ended September 30, 2014, after discrete period adjustments, was 36.9%. Before discrete adjustments the tax rate was 37.6%, which is above the statutory rate due to the impact of state taxes and non-deductible expenses for items such as Incentive Stock Option (“ISO”) expense, meals and entertainment and lobbying fees, but also reduced by the domestic production activities deduction, the net effects of which makes projected annual net income for tax purposes higher than our book pre-tax income.

8. Stockholders’ equity

Stock Option Activity

In May 2013, the Company’s stockholders approved a new stock incentive plan authorizing an additional 1.6 million shares, plus remaining available shares under a prior plan for issuance under the new plan. Combined with the legacy stock incentive plans, there are approximately 1.9 million shares available for grant as of September 30, 2014.

Performance-based stock awards

The Company has issued performance-based stock options and performance-based restricted stock units (“RSUs”), the vesting of which is contingent upon the achievement of certain performance criteria related to the operating performance of the Company as well as successful and timely development and market acceptance of future product introductions. In addition, certain of the performance RSUs have additional service requirements subsequent to the achievement of the performance criteria. Compensation expense is recognized over the implicit service period (the longer of the period the performance condition is expected to be achieved or the required service period) based on management’s estimate of the probability of the performance criteria being satisfied, adjusted at each balance sheet date.

Restricted Stock Units

The following table summarizes RSU activity for the nine months ended September 30, 2014 (number of units and aggregate intrinsic value in thousands):

 

     Number of
Units
    Weighted
Average Grant-

Date Fair Value
     Aggregate
Intrinsic Value
 

Units outstanding, beginning of period

     1,279      $ 9.67      

Granted

     502        16.73      

Released

     (369     7.51      

Forfeited

     (144     12.83      
  

 

 

      

Units outstanding, end of period

     1,268        12.75       $ 19,575   
  

 

 

      

 

14


Table of Contents

TASER INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

Aggregate intrinsic value represents the Company’s closing stock price on the last trading day of the period, which was $15.44 per share on September 30, 2014, multiplied by the number of RSUs outstanding. As of September 30, 2014, there was $11.4 million in unrecognized compensation cost related to RSUs granted under the Company’s stock plans. The Company expect to recognize this cost over a weighted average period of 30 months. RSUs are released when vesting requirements are met.

In the nine months ended September 30, 2014, the Company granted approximately 0.1 million performance-based RSUs, which are included in the table above. Of the approximately 0.3 million performance-based RSUs outstanding as of September 30, 2014, the performance criteria have been met for approximately 0.1 million units, which will vest upon the completion of service requirements. Certain of the performance-based RSUs granted in 2014 contain provisions whereby the amount of RSUs that ultimately vest is dependent upon the level of achievement of performance metrics. The amount of RSUs included in the table above related to such grants is the target level, which is the Company’s best estimate of the amount of RSUs that will vest. The maximum additional number of RSUs that could be earned is approximately 0.1 million, which are not included in the table above.

Certain RSUs that vested in the first nine months of 2014 were net-share settled such that the Company withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total shares withheld were approximately 0.1 million with a value of approximately $1.3 million on their respective vesting dates as determined by the Company’s closing stock price on such dates. Payments for the employees’ tax obligations are reflected as a financing activity within the statement of cash flows. These net-share settlements had the effect of share repurchases by the Company as they reduced the amount of shares that would have otherwise been issued as a result of vesting.

Stock Options

The following table summarizes stock option activity for the nine months ended September 30, 2014 (number of options and aggregate intrinsic value in thousands):

 

     Number of
options
    Weighted
Average
Exercise Price
     Weighted
Average
Remaining
Contractual
Life (years)
     Aggregate
Intrinsic Value
 

Options outstanding, beginning of period

     3,366      $ 6.15         

Granted

     —             

Exercised

     (1,218     7.06         

Expired / forfeited

     (54     10.29         
  

 

 

         

Options outstanding, end of period

     2,094        5.51         4.70       $ 20,925   
  

 

 

         

Exercisable at September 30, 2014

     2,055        5.53         4.70         20,508   
  

 

 

         

Expected to vest after September 30, 2014

     27        4.73         4.89         287   
  

 

 

         

Aggregate intrinsic value represents the difference between the exercise price of the underlying stock option awards and the closing market price of the Company’s common stock of $15.44 on September 30, 2014. The aggregate intrinsic value of options exercised for the three and nine months ended September 30, 2014 was approximately $1.7 million and $14.4 million, respectively. The aggregate intrinsic value of options exercised for the three and nine months ended September 30, 2013 was approximately $5.3 million and $9.1 million, respectively. As of September 30, 2014, total unrecognized stock-based compensation expense related to unvested stock options was approximately $32,000, which is expected to be recognized over a remaining weighted average period of approximately nine months. Options expected to vest are presented net of expected forfeitures.

Included in the table above is approximately 0.4 million of performance-based options of which, 0.3 million are vested. The Company does not expect the remaining performance-based options to vest and does not expect to recognize any future expense related to performance-based stock options.

 

15


Table of Contents

TASER INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

Share-Based Compensation Expense

When granted, the Company calculates the fair value of stock options using the Black-Scholes-Merton option pricing valuation model, which incorporates various assumptions including volatility, expected life and risk-free interest rates. No options were awarded during the nine month periods ended September 30, 2014 or 2013. The estimated fair value of stock-based compensation awards is amortized to expense on a straight-line basis over the service periods. As stock-based compensation expense recognized is based on awards ultimately expected to vest, it is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company’s forfeiture rate was calculated based on its historical experience of awards which ultimately vested.

Share-based compensation was classified as follows (in thousands):

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2014      2013      2014      2013  

Cost of products sold

   $ 61       $ 50       $ 149       $ 134   

Sales, general and administrative expenses

     940         736         2,598         2,293   

Research and development expenses

     436         177         1,374         479   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total share-based compensation

   $ 1,437       $ 963       $ 4,121       $ 2,906   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total share-based compensation expense recognized in the statements of operations for the three months ended September 30, 2014 and 2013, included approximately $2,000 and $22,000, respectively, related to incentive stock options for which no tax benefit is recognized. Total share-based compensation expense recognized in the statements of operations for the nine months ended September 30, 2014 and 2013, included approximately $18,000 and $0.1 million, respectively, related to incentive stock options for which no tax benefit is recognized.

Issuer Purchases of Equity Securities

In May 2014, the Company announced that TASER’s Board of Directors authorized a stock repurchase program to acquire up to $30.0 million of the Company’s outstanding common stock subject to stock market conditions and corporate considerations. During the quarter ended September 30, 2014, the Company purchased approximately 0.2 million common shares under this program for a total cost of approximately $2.9 million, or a weighted average cost of $11.94 per share. The weighted average cost includes the average price paid per share of $11.91, plus any applicable administrative costs for the transaction. During the five month period from inception of the repurchase program through September 30, 2014, the Company purchased approximately 1.7 million common shares under this program for a total cost of approximately $22.4 million, or a weighted average cost of $12.99 per share. The weighted average cost includes the average price paid per share of $12.96, plus any applicable administrative costs for the transaction. The Company has approximately $7.6 million remaining on the repurchase authorization as of September 30, 2014. Repurchases may be made from time to time on the open market.

9. Line of credit

The Company has a $10.0 million revolving line of credit with a domestic bank. As of September 30, 2014, the Company had letters of credit outstanding of approximately $47,000 under the facility. The line is secured by the Company’s accounts receivable and inventory, and bears interest at varying rates (currently LIBOR plus 1.5% to Prime). The line of credit matures on June 30, 2015, and requires monthly payments of interest only. At September 30, 2014 and December 31, 2013, there were no borrowings under the line of credit. The Company’s agreement with the bank requires it to comply with certain financial and other covenants including maintenance of minimum tangible net worth and a fixed charge coverage ratio. The ratio of total liabilities to tangible net worth can be no greater than 1:1, and the fixed charge coverage ratio, as defined in the line of credit, can be no less than 1.25:1, based upon a trailing twelve-month period. At September 30, 2014, the Company’s tangible net worth ratio was 0.40:1 and its fixed charge coverage ratio was 2.86:1, and accordingly, the Company was in compliance with these covenants.

 

16


Table of Contents

TASER INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

10. Commitments and contingencies

Product Litigation

The Company is currently named as a defendant in 16 lawsuits in which the plaintiffs allege either wrongful death or personal injury in situations in which a TASER CEW was used (or present) by law enforcement officers in connection with arrests or during training exercises. In addition, two other product litigation matters in which the Company is involved are currently on appeal. While the facts vary from case to case, the product liability claims are typically based on an alleged product defect resulting in injury or death, usually involving a failure to warn, and the plaintiffs are seeking monetary damages. The information throughout this note is current through the filing date of this Quarterly Report on Form 10-Q.

As a general rule, it is the Company’s policy not to settle suspect injury or death cases. Exceptions are sometimes made where the settlement is strategically beneficial to the Company. Also, on occasion, the Company’s insurance company has settled such lawsuits over the Company’s objection where the exposure exceeds the Company’s liability insurance deductibles. Due to the confidentiality of the Company’s litigation strategy and the confidentiality agreements that are executed in the event of a settlement, the Company does not generally identify or comment on which specific lawsuits have been settled or the amount of any settlement.

In 2009, the Company implemented new risk management strategies, including revisions to product warnings and training to better protect both the Company and its customers from litigation based on ‘failure to warn’ theories – which comprise the vast majority of the cases against the Company. These risk management strategies have been highly effective in reducing the rate and exposure from litigation post-2009. From the third quarter of 2011 to the third quarter of 2014, we have reduced our outstanding product liability cases from 55 active to 16 active cases.

Management believes that pre-2009 cases have a different risk profile than cases which have occurred since the risk management procedures were introduced in 2009. Therefore, the Company necessarily treats certain pre-2009 cases as exceptions to the Company’s general no settlement policy in order to reduce caseload, legal costs and liability exposure. The Company intends to continue its successful practice of aggressively defending and generally not settling litigation except in very limited and unusual circumstances as described above.

With respect to each of the pending lawsuits, the following table lists the name of plaintiff, the date the Company was served with process, the jurisdiction in which the case is pending, the type of claim and the status of the matter.

 

Plaintiff

  

Served

  

Jurisdiction

  

Claim Type

   Status

Grable

   Aug-08    6th Judicial Circuit Court, Pinellas County, FL    Training Injury    Discovery Phase

Koon

   Dec-08    17th Judicial Circuit Court, Broward County, FL    Training Injury    Discovery Phase

Derbyshire

   Nov-09    Ontario, Canada Superior Court of Justice    Officer Injury    Discovery Phase

Thompson

   Mar-10    11th Judicial Circuit Court, Miami-Dade County, FL    Suspect Injury During Arrest    Discovery Phase

Doan

   Apr-10    The Queens Bench Alberta, Red Deer Judicial Dist.    Wrongful Death    Discovery Phase

Shymko

   Dec-10    The Queens Bench, Winnipeg Centre, Manitoba    Wrongful Death    Pleading Phase

Juran

   Dec-10    Hennepin County District Court, 4th Judicial District    Officer Injury    Pleading Phase

Wilson

   May-11    US District Court, ED MO    Wrongful Death    Trial scheduled
for Nov. 2014

Ramsey

   Jan-12    17th Judicial Circuit Court, Broward County, FL    Wrongful Death    Discovery Phase

Firman

   Apr-12    Ontario, Canada Superior Court of Justice    Wrongful Death    Pleading Phase

Ricks

   May-12    US District Court, WD LA    Wrongful Death    Motion Phase

Miller

   Jan-13    New Castle County Superior Court, DE    Wrongful Death    Discovery Phase

Rascom

   Apr-14    US District Court, AZ    Wrongful Death    Pleading Phase

Schrock

   Sep-14    San Bernardino County Superior Court, CA    Wrongful Death    Pleading Phase

Ward

   Oct-14    Richmond County Superior Court, GA    Officer Fired    Pleading Phase

Moore

   Oct-14    St. Louis County Circuit Court, MO    Wrongful Death    Pleading Phase

In addition, other product litigation matters in which the Company is involved that are currently on appeal are listed below:

 

Plaintiff

   Month
Served
    

Jurisdiction

   Claim Type     

Status

Glowczenski

     Oct-04       US District Court, ED NY      Wrongful Death       Notice of Appeal filed Sep. 2013; Opening Brief was filed Jan. 2014; Answering Brief filed Apr. 2014.

Mitchell

     Apr-12       US District Court, ED MI      Wrongful Death       Notice of Appeal filed Aug. 2014

 

17


Table of Contents

TASER INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

Cases that were dismissed or judgment entered during the third quarter of 2014, and through the filing date of this Quarterly Report on Form 10-Q, are listed in the table below. Cases that were dismissed or judgment entered in prior fiscal quarters are not included in this table.

 

Plaintiff

   Month
Served
    

Jurisdiction

  

Claim Type

   Status

Faltesek

     Apr-14       Harris County District Court, TX    Wrongful Death    Voluntary Dismissal

Mitchell

     Apr-12       US District Court, ED MI    Wrongful Death    Motion for
Summary Judgment
Granted

McCue

     Mar-14       US District Court, District of Maine    Wrongful Death    Voluntary Dismissal

Slade

     Dec-13       US District Court, ED TX    Wrongful Death    Voluntary Dismissal

Goodard

     Jul-14       Pinellas County Circuit Court, FL    Wrongful Death    Voluntary Dismissal

Parker

     Jul-14       US District Court, SD TX    Suspect Injury During Arrest    Voluntary Dismissal

The claims, and in some instances the defense, of each of these lawsuits have been submitted to the Company’s insurance carriers that maintained insurance coverage during the applicable periods. The Company continues to maintain product liability insurance coverage with varying limits and deductibles. The following table provides information regarding the Company’s product liability insurance. Remaining insurance coverage is based on information received from the Company’s insurance provider (in millions).

 

Policy Year

   Policy
Start Date
     Policy
End Date
     Insurance
Coverage
     Deductible
Amount
     Defense
Costs
Covered
     Remaining
Insurance
Coverage
    

Active Cases and Cases on Appeal

2004

     12/01/03         12/01/04       $ 2.0       $ 0.1         N       $ 2.0       Glowczenski

2005

     12/01/04         12/01/05         10.0         0.3         Y         7.0       n/a

2006

     12/01/05         12/01/06         10.0         0.3         Y         3.7       n/a

2007

     12/01/06         12/01/07         10.0         0.3         Y         8.0       n/a

2008

     12/01/07         12/15/08         10.0         0.5         Y         —         Grable, Koon

2009

     12/15/08         12/15/09         10.0         1.0         N         10.0       Derbyshire

2010

     12/15/09         12/15/10         10.0         1.0         N         10.0       Thompson, Shymko, Doan, Juran

2011

     12/15/10         12/15/11         10.0         1.0         N         10.0       Wilson

Jan – Jun 2012

     12/15/11         06/25/12         7.0         1.0         N         7.0       Ramsey, Firman, Ricks, Mitchell

Jul – Dec 2012

     06/25/12         12/15/12         12.0         1.0         N         12.0       n/a

2013

     12/15/12         12/15/13         12.0         1.0         N         12.0       Miller

2014

     12/15/13         12/15/14         12.0         4.0         N         12.0       Rascom, Schrock, Moore, Ward

Other Litigation

AA & Saba (AZ) Lawsuit

In February 2012, the Company was served with a complaint in the matter of AA & Saba Consultants, Inc. v. TASER International, Inc. that was filed in the Superior Court for the County of Maricopa, Arizona, which alleges that the Company breached a contract by unilaterally terminating a distributor agreement between the Company and plaintiff without good cause. The complaint seeks an award for damages, costs, expenses and attorneys’ fees. TASER filed a counterclaim for breach of contract and fraud. During 2012, the Company made a settlement offer of $0.8 million to plaintiff, which was recorded as an expense in SG&A in that year. The offer was not accepted and thereafter was withdrawn. On February 28, 2014, the jury returned a verdict of $3.3 million against the Company. Judgment had not been entered at the time. The Company recorded an additional $2.6 million of expense in the fourth quarter of 2013 as Litigation judgments on the statement of operations.

On May 6, 2014 the court issued a Minute Entry Order awarding Plaintiff approximately $1.2 million in attorneys’ fees, costs and expenses which was recorded as a litigation settlement in the second quarter of 2014. On May 6, 2014 the matter was resolved and dismissed.

 

18


Table of Contents

TASER INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

General

From time to time, the Company is notified that it may be a party to a lawsuit or that a claim is being made against it. It is the Company’s policy to not disclose the specifics of any claim or threatened lawsuit until the summons and complaint are actually served on the Company. After carefully assessing the claim, and assuming we determine that we are not at fault or we disagree with the damages or relief demanded, we vigorously defend any lawsuit filed against the Company. In certain legal matters, we record a liability when losses are deemed probable and reasonably estimable. In evaluating matters for accrual and disclosure purposes, we take into consideration factors such as our historical experience with matters of a similar nature, the specific facts and circumstances asserted, the likelihood of our prevailing, and the severity of any potential loss. We reevaluate and update our accruals as matters progress over time.

Based on our assessment of outstanding litigation and claims as of September 30, 2014, the Company has determined that it is not reasonably possible that these lawsuits will individually, or in the aggregate, materially affect our results of operations, financial condition or cash flows. However, the outcome of any litigation is inherently uncertain and there can be no assurance that any expense, liability or damages that may ultimately result from the resolution of these matters will be covered by our insurance or will not be in excess of amounts recognized or provided by insurance coverage and will not have a material adverse effect on our operating results, financial condition or cash flows.

11. Related party transactions

The Company engages Mark Kroll, a member of the Board of Directors, to provide consulting services. Expenses relating to these services for the three months ended September 30, 2014 and 2013 were approximately $50,000 and $59,000, respectively. Expenses relating to these services for the nine months ended September 30, 2014 and 2013 were approximately $121,000 and $125,000, respectively. At September 30, 2014 and December 31, 2013, the Company had accrued liabilities for these consulting services of approximately $26,000 and $12,000, respectively.

12. Employee benefit plans

The Company has a defined contribution profit sharing 401(k) plan for eligible employees, which is qualified under Sections 401(a) and 401(k) of the Internal Revenue Code of 1986, as amended. Employees are entitled to make tax-deferred contributions of up to the maximum allowed by law of their eligible compensation.

In addition, during 2013, the Company implemented a non-qualified deferred compensation plan for certain executives, key employees and non-employee directors through which participants may elect to postpone the receipt and taxation of a portion of their compensation, including stock-based compensation, received from the Company. The non-qualified deferred compensation plan allows eligible participants to defer up to 80% of their base salary and up to 100% of other types of compensation. The plan also allows for (i) matching and discretionary employer contributions and (ii) the deferral of vested RSU awards. Employee deferrals are deemed 100% vested upon contribution. Distributions from the plan are made upon retirement, death, separation of service, specified date or upon the occurrence of an unforeseeable emergency. Distributions can be paid in a variety of forms from lump sum to installments over a period of years. Participants in the plan are entitled to select from a wide variety of investments available under the plan for their cash contributions and are allocated gains or losses based upon the performance of the investments selected by the participant. All gains or losses are allocated fully to plan participants and the Company does not guarantee a rate of return on deferred balances. Assets related to this plan consist of corporate-owned life insurance contracts and are included in Other assets in the condensed consolidated balance sheets. Participants have no rights or claims with respect to any plan assets and any such assets are subject to the claims of the Company’s general creditors.

Contributions to the plans are made by both the employee and the Company. Company contributions are based on the level of employee contributions and are immediately vested. The Company’s matching contributions to the 401(k) plan for the three months ended September 30, 2014 and 2013, were both approximately $0.2 million. The Company’s matching contributions to the 401(k) plan for the nine months ended September 30, 2014 and 2013, were $0.6 million and $0.5 million, respectively. The Company has recorded matching contributions to the non-qualified deferred compensation plan related to the three and nine months ended September 30, 2014, of approximately $6,000 and $20,000, respectively. The Company made matching contributions of approximately $6,000 to the non-qualified deferred compensation plan for the three and nine months ended September 30, 2013. Future matching or profit sharing contributions to the plans are at the Company’s sole discretion.

 

19


Table of Contents

TASER INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

 

13. Segment data

The Company’s operations are comprised of two reportable segments: the manufacture and sale of CEWs, accessories and other products and services (the “TASER Weapons” segment); and the video business, which includes the TASER Cam, AXON video products and EVIDENCE.com (the “EVIDENCE.com & Video” segment). The Company includes only revenues and costs directly attributable to the EVIDENCE.com & Video segment in that segment. Included in EVIDENCE.com & Video segment costs are costs of sales for both products and services, overhead allocation based on direct labor, selling expense for the video sales team, video product management expenses, video trade shows and related expenses, and research and development for products included in the EVIDENCE.com & Video segment. All other costs are included in the TASER Weapons segment. The CODM does not review assets by segment as part of the financial information provided; therefore, no asset information is provided in the following tables.

Information relative to the Company’s reportable segments is as follows (in thousands):

 

     Three Months Ended September 30, 2014      Three Months Ended September 30, 2013  
     TASER      EVIDENCE.com            TASER      EVIDENCE.com        
     Weapons      & Video     Total      Weapons      & Video     Total  

Product sales

   $ 40,010       $ 3,181      $ 43,191       $ 31,627       $ 3,103      $ 34,730   

Service revenue

     —           1,158        1,158         —           467        467   
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

Net sales

     40,010         4,339        44,349         31,627         3,570        35,197   
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

Cost of products sold

     12,443         2,695        15,138         10,908         1,896        12,804   

Cost of services delivered

     —           498        498         —           297        297   
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

Gross margin

     27,567         1,146        28,713         20,719         1,377        22,096   

Sales, general and administrative expenses

     10,028         2,413        12,441         11,131         1,645        12,776   

Research and development expenses

     1,050         2,709        3,759         1,160         1,279        2,439   
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

Income (loss) from operations

   $ 16,489       $ (3,976   $ 12,513       $ 8,428       $ (1,547   $ 6,881   
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

Purchases of property and equipment

   $ 803       $ 41      $ 844       $ 230       $ 105      $ 335   

Purchases of intangible assets

     14         2        16         67         2        69   

Depreciation and amortization

     1,010         91        1,101         1,025         63        1,088   
     Nine Months Ended September 30, 2014      Nine Months Ended September 30, 2013  
     TASER      EVIDENCE.com            TASER      EVIDENCE.com        
     Weapons      & Video     Total      Weapons      & Video     Total  

Product sales

   $ 105,160       $ 9,812      $ 114,972       $ 89,902       $ 6,853      $ 96,755   

Service revenue

     —           2,737        2,737         —           1,051        1,051   
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

Net sales

     105,160         12,549        117,709         89,902         7,904        97,806   
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

Cost of products sold

     34,024         8,111        42,135         31,535         4,440        35,975   

Cost of services delivered

     —           1,439        1,439         —           1,542        1,542   
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

Gross margin

     71,136         2,999        74,135         58,367         1,922        60,289   

Sales, general and administrative expenses

     32,218         7,516        39,734         30,622         4,276        34,898   

Research and development expenses

     2,660         8,160        10,820         3,126         3,318        6,444   
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

Income (loss) from operations

   $ 36,258       $ (12,677   $ 23,581       $ 24,619       $ (5,672   $ 18,947   
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

 

Purchases of property and equipment

   $ 1,836       $ 230      $ 2,066       $ 828       $ 346      $ 1,174   

Purchases of intangible assets

     123         2        125         260         11        271   

Depreciation and amortization

     3,078         290        3,368         2,998         1,038        4,036   

 

20


Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following is a discussion of the Company’s financial condition as of September 30, 2014, and results of operations for the three and nine months ended September 30, 2014 and 2013. The following discussion may be understood more fully by reference to the consolidated financial statements, notes to the consolidated financial statements, and Management’s Discussion and Analysis of Financial Condition and Results of Operations section contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

Certain statements contained in this report may be deemed to be forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, and the Company intends that such forward-looking statements be subject to the safe-harbor created thereby. Such forward-looking statements may relate to, among other things: the impact of recently issued and adopted accounting standards and guidance; the gross margins in the EVlDENCE.com & Video Segment will be lower in the near term; that increased marketing expenditure will lead to sales growth; our anticipation that government contracts will be completed; that fixed costs in our EVIDENCE.com & Video segment will remain stable and result in a lower cost of services delivered as a percentage of revenue; that R&D and SG&A expenses will continue to increase in the remainder of 2014 and into 2015; the characteristics of our pending claims, our litigation strategy and the outcome of pending litigation against us; the sufficiency of our valuation reserves, including warranty, accounts receivable, deferred taxes and inventory reserves; our projected effective tax rate for 2014; the sufficiency of our capital resources and the availability of financing to the Company; changes in our unrecognized tax benefits; that we will realize our deferred tax assets; our intentions to hold investments to maturity; and our strategy with respect to hedging activities. We caution that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by the forward looking statements herein. Such factors include, but are not limited to: market acceptance of our products; our dependence on sales of our TASER X26, X26P and X2 CEWs; the acceptance of our EVIDENCE.com software model; our ability to design, introduce and sell new products; delays in development schedules; rapid technological change and competition; product defects; breach of our security measures resulting in unauthorized access to customer data; outages and disruptions relating to our EVIDENCE.com service; budgetary and political constraints of prospects and customers; our exposure to cancellations of government contracts due to appropriation clauses; the length of our sales cycle and our ability to realize benefits from our marketing and selling efforts; the long-term revenue recognition cycle for our SaaS EVIDENCE.com product; regulatory and political challenges presented by international markets; litigation risks resulting from alleged product-related injuries and media publicity concerning allegations of deaths occurring after use of the TASER device and the negative impact this publicity could have on sales; the outcome of pending or future litigation; our ability to protect our intellectual property; intellectual property infringement claims and relating litigation costs; competition in foreign countries relating to foreign patents; our successful identification of existing intellectual property rights that might infringe on our developments; risks of governmental regulations, including regulations of our products by the United States Consumer Product Safety Commission, regulation of our products as a “crime control” product by the Federal government, state and local government regulation and foreign regulation and the adverse effects that could result from our products being classified as firearms by the United States Bureau of Alcohol and Firearms; our compliance with regulations governing the environment, including but not limited to, regulations within the European Union; new regulations relating to conflict minerals; our dependence on third party suppliers for key components of our products; component shortages; rising costs of raw materials and transportation relating to petroleum prices; our ability to manage our growth and increase manufacturing production to meet demand; establishment and expansion of our direct and indirect distribution channels; our ability to pursue sales directly with customers; risks relating to acquisitions and joint ventures; catastrophic events; fluctuations in quarterly operating results; foreign currency fluctuations; counterparty risks relating to cash balances held in excess of FDIC insurance limits; employee retention risks and other factors identified in documents filed by us with the Securities and Exchange Commission, including those set forth in our Form 10-K for the year ended December 31, 2013.

Overview

TASER International, Inc.’s (the “Company” or “TASER” or “we” or “our”) core mission is to protect life and to protect truth through technologies that make communities safer. We are the market leader in the development, manufacture and sale of conducted electrical weapons (“CEWs”) and other electronic weapons designed for use in law enforcement, military, corrections, private security and personal defense. To address challenges faced by law enforcement officers subsequent to post-incident, we have developed a fully integrated hardware and software solution to provide our law enforcement customers the capabilities to capture, store, manage, share and analyze video and other digital evidence.

 

21


Table of Contents

Results of Operations

Three Months Ended September 30, 2014 Compared to the Three Months Ended September 30, 2013

The following table sets forth, for the periods indicated, our unaudited condensed consolidated statements of operations as well as the percentage relationship to total net sales of items included in our condensed consolidated statements of operations (dollars in thousands):

 

     Three Months Ended September 30,     Increase / (Decrease)  
     2014     2013     $     %  

Net sales

   $ 44,349        100.0   $ 35,197         100.0   $ 9,152        26.0

Cost of products sold and services delivered

     15,636        35.3        13,101         37.2        2,535        19.3   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

Gross margin

     28,713        64.7        22,096         62.8        6,617        29.9   

Sales, general and administrative expenses

     12,441        28.1        12,776         36.3        (335     (2.6

Research and development expenses

     3,759        8.5        2,439         6.9        1,320        54.1   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

Income from operations

     12,513        28.2        6,881         19.5        5,632        81.8   

Interest and other income (expense), net

     (160     (0.4     35         0.1        (195     *   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

Income before provision for income taxes

     12,353        27.9        6,916         19.6        5,437        78.6   

Provision for income taxes

     4,795        10.8        1,802         5.1        2,993        166.1   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

Net income

   $ 7,558        17.0   $ 5,114         14.5   $ 2,444        47.8   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

 

* Not meaningful

Net Sales

Net sales by product line were as follows (dollars in thousands):

 

     Three Months Ended September 30,     Increase / (Decrease)  
     2014     2013     $     %  

TASER Weapons segment:

             

TASER X26

   $ 2,694        6.1   $ 7,229         20.5   $ (4,535     (62.7 )% 

TASER X2

     10,719        24.2        7,645         21.7        3,074        40.2   

TASER X26P

     13,670        30.8        5,557         15.8        8,113        146.0   

TASER C2

     463        1.0        452         1.3        11        2.4   

M26

     184        0.4        160         0.5        24        15.0   

Single Cartridges

     9,435        21.3        8,227         23.4        1,208        14.7   

StrikeLight

     13        0.0        142         0.4        (129     (90.8

Extended Warranties including TAP

     1,761        4.0        1,196         3.4        565        47.2   

Other

     1,071        2.4        1,019         2.9        52        5.1   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

TASER Weapons segment

     40,010        90.2        31,627         89.9        8,383        26.5   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

EVIDENCE.com & Video segment:

             

AXON

     2,455        5.5        1,221         3.5        1,234        101.1   

EVIDENCE.com

     1,050        2.4        467         1.3        583        124.8   

TASER Cam

     950        2.1        1,784         5.1        (834     (46.7

Other

     (116     *        98         0.3        (214     *   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

EVIDENCE.com & Video segment

     4,339        9.8        3,570         10.1        769        21.5   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

Total net sales

   $ 44,349        100.0   $ 35,197         100.0   $ 9,152        26.0   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

 

* Not meaningful

 

22


Table of Contents

Net unit sales for the TASER Weapons products and EVIDENCE.com & Video segment products are as follows:

 

     Three Months Ended September 30,  
                   Unit     Percent  
     2014      2013      Change     Change  

TASER X26

     2,775         7,195         (4,420     (61.4 )% 

TASER X2

     10,694         8,469         2,225        26.3   

TASER X26P

     15,466         7,327         8,139        111.1   

TASER C2

     1,462         1,544         (82     (5.3

M26

     499         502         (3     (0.6

Single Cartridges

     403,613         375,363         28,250        7.5   

StrikeLight

     350         1,322         (972     (73.5

TASER XREP

     —           —           —          *   

AXON flex

     2,577         1,217         1,360        111.8   

AXON body

     3,224         774         2,450        316.5   

TASER Cam

     1,967         3,343         (1,376     (41.2

 

* Not meaningful

Net sales to the United States and other countries are summarized as follows (dollars in thousands):

 

     Three Months Ended September 30,  
     2014     2013  

United States

   $ 37,605         84.8   $ 31,483         89.4

Other Countries

     6,744         15.2        3,714         10.6   
  

 

 

    

 

 

   

 

 

    

 

 

 

Total

   $ 44,349         100.0   $ 35,197         100.0
  

 

 

    

 

 

   

 

 

    

 

 

 

Net sales were $44.3 million and $35.2 million for the three months ended September 30, 2014 and 2013, respectively, an increase of $9.2 million, or 26.0%. The increase in net sales for the third quarter of 2014 compared to 2013 was primarily driven by the continued adoption of the TASER X26P Smart Weapon, which contributed $13.7 million of sales for the third quarter of 2014, an increase of $8.1 million compared to the third quarter of the prior year. Total law enforcement weapon handles sales in the third quarter were $27.4 million compared to prior year third quarter sales of $20.4 million. Sales of the TASER X26 CEW decreased $4.4 million in the third quarter of 2014 when compared to the same period in the previous year as a result of customers embracing the X26P SMART Weapon platform.

Revenue relative to our EVIDENCE.com & Video segment increased $0.8 million to $4.3 million for the three months ended September 30, 2014, due to additional revenue recognized from higher sales of our AXON on-officer cameras and our EVIDENCE.com SaaS partially offset by lower sales of TASER Cams. AXON body was launched in the third quarter of 2013 and AXON flex was launched in 2012. Revenue related to EVIDENCE.com is recognized over the requisite service period of one to five years.

To gain more immediate feedback regarding activity for AXON flex, AXON body and EVIDENCE.com, we also review bookings for these products. We consider bookings to be a statistical measure defined as the sales price of orders (not invoiced sales) placed in the relevant fiscal period, regardless of when the products or services ultimately will be provided. Some bookings will be invoiced in subsequent periods. Due to municipal government funding rules, certain of the future period amounts included in bookings are subject to budget appropriation or other contract cancellation clauses. Although TASER has entered into contracts for the delivery of products and services in the future and anticipates the contracts will be completed, if agencies do not appropriate funds in future year budgets or invoke a cancellation clause, revenue associated with these bookings will not ultimately be recognized, resulting in a future reduction to bookings. Bookings related to EVIDENCE.com, AXON body and AXON flex increased to $15.3 million during the three months ended September 30, 2014, compared to $5.8 million in the same quarter in the prior year. We continue to generate traction with a number of new agencies adopting this platform.

International sales for the third quarter of 2014 and 2013 represented approximately $6.7 million, or 15.2%, and $3.7 million, or 10.6%, of total net sales, respectively. Sales in the international market generally are larger and occur more intermittently than in the domestic market due to the profile of the customers.

 

23


Table of Contents

Cost of Products Sold and Services Delivered

Cost of products sold and services delivered were $15.6 million and $13.1 million for the three months ended September 30, 2014 and 2013, respectively, an increase of $2.5 million, or 19.3%. As a percentage of net sales, cost of products sold and services delivered decreased to 35.3% in the third quarter of 2014 compared to 37.2% in the third quarter of 2013. Cost of products sold for our TASER Weapons segment were $12.4 million for the three months ended September 30, 2014, or 31.1% of TASER Weapons segment sales, compared to $10.9 million for the three months ended September 30, 2013, or 34.5% of TASER Weapons segment sales. The decrease as a percentage of net sales is primarily derived from increased leverage due to higher sales and higher average selling prices.

Cost of products sold and services delivered for the EVIDENCE.com & Video segment were $3.2 million for the third quarter of 2014, an increase of $1.0 million, or 45.6% from the third quarter of 2013. Increased product costs related to the EVIDENCE.com & Video segment related to growing sales in this segment. Service costs related to the EVIDENCE.com & Video segment increased approximately $0.2 million as a result of increased travel costs due to more implementation services as well has higher cloud storage fees as more data is saved on EVIDENCE.com. As a percentage of net sales, cost of products sold and services delivered increased to 73.6% in the third quarter of 2014 from 61.4% in the third quarter of 2013. There are a number of fixed costs for the EVIDENCE.com & Video segment which, as we generate traction in the business, we expect to remain relatively stable and should allow for lower cost of services delivered as a percentage of service revenue.

Gross Margin

Gross margin was $28.7 million and $22.1 million for the three months ended September 30, 2014 and 2013, respectively, an increase of $6.6 million, or 29.9%. Our gross margin as a percent of sales increased to 64.7% for the third quarter of 2014 compared to 62.8% for the third quarter of 2013, a result of the factors discussed above under Costs of products sold and services delivered as well as leverage in overhead expense from increased sales and increased sales prices. In the fourth quarter of 2013, we introduced a new pricing program reducing the price of the AXON cameras and separately pricing the EVIDENCE.com service. In previous quarters, the cameras and service were primarily sold together with one price for both. We believe lowering the price of the cameras and offering separately-priced EVIDENCE.com SaaS contracts at various levels of functionality promotes pricing transparency for our customers. As a result, the gross margins in the EVIDENCE.com & Video segment are expected to be lower in the near-term as the service portion is deferred and recognized over the contract term. The AXON flex and the AXON body are currently being sold at low gross margins in an effort to continue to accelerate the Company’s traction in the market.

Sales, General and Administrative Expenses

For the three months ended September 30, 2014 and 2013, SG&A expenses were comprised of the following (dollars in thousands):

 

     Three Months Ended September 30,  
                 $     %  
     2014     2013     Change     Change  

Salaries, benefits and bonus

   $ 4,585      $ 3,555      $ 1,030        29.0

Professional, accounting and legal fees and litigation expenses *

     1,326        3,529        (2,203     (62.4

Office expenses

     1,099        1,054        45        4.3   

Travel and meals

     1,056        865        191        22.1   

Stock-based compensation

     940        736        204        27.7   

Consulting and lobbying

     695        484        211        43.6   

Depreciation and amortization

     325        296        29        9.8   

Sales and marketing *

     1,740        1,555        185        11.9   

Liability insurance

     351        503        (152     (30.2

Other

     324        199        125        62.8   
  

 

 

   

 

 

   

 

 

   

Total

   $ 12,441      $ 12,776      $ (335     (2.6
  

 

 

   

 

 

   

 

 

   

Sales, general and administrative as a % of net sales

     28.1     36.3    

 

* Sales and marketing, and Professional, accounting and legal fees and litigation expenses are presented excluding salaries, benefits and stock compensation for those departments. Compensation related expenses for those areas are captured in the “Salaries, benefits and bonus” and “Stock-based compensation” lines.

 

24


Table of Contents

SG&A expenses were $12.4 million and $12.8 million for the three months ended September 30, 2014 and 2013, respectively, a decrease of $0.4 million, or 2.6%. As a percentage of net sales, SG&A expenses decreased to 28.1% for the third quarter of 2014 compared to 36.3% for the third quarter of 2013.

Within the TASER Weapons segment, SG&A decreased $1.1 million, or 9.9%, to $10.0 million in the third quarter of 2014 from $11.1 million in the third quarter of 2013. Sales and marketing expense decreased approximately $1.1 million compared to the prior year due to the timing of the International Association of Chiefs of Police conference, which will be held in the fourth quarter of 2014. Legal, professional and accounting fees also decreased approximately $0.9 million compared to the prior year which had higher expenses relating to the defense of product and commercial litigation. These decreases were partially offset by increased personnel expenses of approximately $0.7 million due to increased international, sales and administrative personnel as the Company supports its growing infrastructure.

Within the EVIDENCE.com & Video segment, SG&A increased $0.8 million, or 46.7%, to $2.4 million in the third quarter of 2014 in comparison to the prior year. Salaries, benefits and bonus and stock compensation in the EVIDENCE.com & Video segment increased $0.5 million primarily as a result of the Company increasing its video salesforce and hiring incremental functions such as implementation services, account management, public relations and other customer-facing roles. Travel expense for the EVIDENCE.com & Video segment increased $0.2 million compared to the prior year as a result of increased sales personnel and international travel. Consulting and lobbying expenses also increased approximately $0.2 million compared to the prior year.

The Company expects to see increased SG&A in the fourth quarter due to the timing of the International Association of Chiefs of Police conference which will occur in the fourth quarter of 2014. The Company also expects higher SG&A expenses for the fourth quarter 2014 and into 2015 as the Company continues to invest and grow the infrastructure necessary to achieve its initiatives of increasing revenues internationally and in the EVIDENCE.com & Video segment.

Research and Development Expenses

Research and development (“R&D”) expenses were $3.8 million for the three months ended September 30, 2014 an increase of $1.3 million or 54.1% over the same period in the prior year. As a percentage of net sales, R&D expense increased to 8.5% in the third quarter of 2014 in comparison to 6.9% in the third quarter of 2013. Research and development expense increased primarily due to additional personnel expense related to EVIDENCE.com & Video segment development initiatives. In the TASER Weapons segment, R&D expenses decreased slightly in comparison to the same period in the previous year as incremental resources are focused on developing our next generation products and features for the EVIDENCE.com & Video segment.

The Company continues to expect increased expenses in R&D in the fourth quarter of 2014 and into 2015 as it adds new functionality and new capabilities to the EVIDENCE.com platform.

Provision for Income Taxes

The provision for income taxes was $4.8 million for the three months ended September 30, 2014, which was an effective tax rate of 38.8%. Our estimated full year effective tax rate for 2014, before discrete period adjustments, is approximately 37.6%, which is above the statutory rate due to the impact of state taxes and non-deductible expenses for items such as ISO stock option expense, meals and entertainment and lobbying fees, but also reduced by the domestic production activities deduction, the net effects of which makes our projected annual net income for tax purposes higher than our book pre-tax income.

Net Income

Our net income increased to $7.6 million, or $0.14 per diluted share, for the third quarter of 2014 compared to net income of $5.1 million, or $0.10 per diluted share, for the third quarter of 2013.

 

25


Table of Contents

Nine Months Ended September 30, 2014 Compared to the Nine Months Ended September 30, 2013

The following table sets forth, for the periods indicated, our unaudited condensed consolidated statements of operations as well as the percentage relationship to total net sales of items included in our condensed consolidated statements of operations (dollars in thousands):

 

     Nine Months Ended September 30,     Increase / (Decrease)  
     2014     2013     $     %  

Net sales

   $ 117,709        100.0   $ 97,806         100.0   $ 19,903        20.3

Cost of products sold

     43,574        37.0        37,517         38.4        6,057        16.1   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

Gross margin

     74,135        63.0        60,289         61.6        13,846        23.0   

Sales, general and administrative expenses

     39,734        33.8        34,898         35.7        4,836        13.9   

Research and development expenses

     10,820        9.2        6,444         6.6        4,376        67.9   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

Income from operations

     23,581        20.0        18,947         19.4        4,634        24.5   

Interest and other income (expense), net

     (88     (0.1     31         0.0        (119     *   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

Income before provision for income taxes

     23,493        20.0        18,978         19.4        4,515        23.8   

Provision for income taxes

     8,661        7.4        6,109         6.2        2,552        41.8   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

Net income

   $ 14,832        12.6   $ 12,869         13.2   $ 1,963        15.3   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

   

 

* Not meaningful

Net Sales

Net sales by product line were as follows (dollars in thousands):

 

     Nine Months Ended September 30,     Increase / (Decrease)  
     2014     2013     $     %  

TASER Weapons segment:

              

TASER X26

   $ 14,509         12.3   $ 22,258         22.8   $ (7,749     (34.8 )% 

TASER X2

     20,038         17.0        18,822         19.2        1,216        6.5   

TASER X26P

     31,825         27.0        13,574         13.9        18,251        134.5   

TASER C2

     1,401         1.2        1,809         1.8        (408     (22.6

M26

     494         0.4        567         0.6        (73     (12.9

Single Cartridges

     26,909         22.9        26,088         26.7        821        3.1   

StrikeLight

     183         0.2        131         0.1        52        39.7   

TASER XREP

     2,615         2.2        —           0.0        2,615        *   

Extended Warranties

     4,517         3.8        3,320         3.4        1,197        36.1   

Other

     2,669         2.3        3,333         3.4        (664     (19.9
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

TASER Weapons segment

     105,160         89.3        89,902         91.9        15,258        17.0   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

EVIDENCE.com & Video segment:

              

AXON

     5,526         4.7        2,729         2.8        2,797        102.5   

EVIDENCE.com

     2,630         2.2        1,051         1.1        1,579        150.2   

TASER Cam

     3,695         3.1        3,707         3.8        (12     (0.3

Other

     698         0.6        417         0.4        281        67.4   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

EVIDENCE.com & Video segment

     12,549         10.7        7,904         8.1        4,645        58.8   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

Total net sales

   $ 117,709         100.0   $ 97,806         100.0   $ 19,903        20.3   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

* Not meaningful

 

26


Table of Contents

Net unit sales for the TASER Weapons products and EVIDENCE.com & Video segment products are as follows:

 

     Nine Months Ended September 30,  
     2014      2013      Unit
Change
    Percent
Change
 

TASER X26

     14,220         24,296         (10,076     (41.5 )% 

TASER X2

     18,673         20,431         (1,758     (8.6

TASER X26P

     36,673         17,663         19,010        107.6   

TASER C2

     5,003         5,869         (866     (14.8

M26

     1,377         1,638         (261     (15.9

Single Cartridges

     1,142,663         1,153,825         (11,162     (1.0

StrikeLight

     2,767         1,322         1,445        109.3   

TASER XREP

     3,770         —           3,770        *   

AXON flex

     6,176         3,580         2,596        72.5   

AXON body

     8,651         774         7,877        *   

TASER Cam

     7,174         8,349         (1,175     (14.1

 

* Not meaningful

Net sales to the United States and other countries are summarized as follows (dollars in thousands):

 

     Nine Months Ended September 30,  
     2014     2013  

United States

   $ 95,336         81.0   $ 86,036         88.0

Other Countries

     22,373         19.0        11,770         12.0   
  

 

 

    

 

 

   

 

 

    

 

 

 

Total

   $ 117,709         100.0   $ 97,806         100.0
  

 

 

    

 

 

   

 

 

    

 

 

 

Net sales were $117.7 million and $97.8 million for the nine months ended September 30, 2014 and 2013, respectively, an increase of $19.9 million, or 20.3%. The increase in net sales for the nine months of 2014 compared to 2013 was primarily driven by the continued adoption of the TASER X26P Smart Weapon, which contributed $31.8 million of sales for the first nine months of 2014 and accounted for $18.3 million of the increase. Sales of the TASER X26 CEW decreased $7.7 million in the first nine months of 2014 when compared to the same period in the previous year as a result of customers embracing the X26P SMART Weapon platform.

Revenue relative to our EVIDENCE.com & Video segment of $12.5 million, increased $4.6 million for the nine months ended September 30, 2014 compared to the same period in the prior year, due to additional revenue recognized from higher sales of our AXON on-officer cameras. Service revenue related to the implementation of our AXON and EVIDENCE.com solution also contributed to the increase in the first nine months of 2014. AXON body was launched in the third quarter of 2013 and AXON flex was launched in 2012. Revenue related to EVIDENCE.com is recognized over the requisite service period of one to five years.

To gain more immediate feedback regarding activity for AXON flex, AXON body and EVIDENCE.com, we also review bookings for these products. We consider bookings to be a statistical measure defined as the sales price of orders (not invoiced sales) placed in the relevant fiscal period, regardless of when the products or services ultimately will be provided. Some bookings will be invoiced in subsequent periods. Due to municipal government funding rules, certain of the future period amounts included in bookings are subject to budget appropriation or other contract cancellation clauses. Although TASER has entered into contracts for the delivery of products and services in the future and anticipates the contracts will be completed, if agencies do not appropriate funds in future year budgets or invoke a cancellation clause, revenue associated with these bookings will not ultimately be recognized, resulting in a future reduction to bookings. Bookings related to EVIDENCE.com and AXON flex increased to $32.5 million during the nine months ended September 30, 2014, compared to $9.3 million in the same period in the prior year. We continue to generate traction with a number of new agencies adopting the platform.

International sales for the first nine months of 2014 and 2013 represented approximately $22.4 million, or 19.0%, and $11.8 million, or 12.0%, of total net sales, respectively. Sales in the international market are generally larger on a per-sale basis and occur more intermittently than in the domestic market due to the profile of the customers.

 

27


Table of Contents

Cost of Products Sold and Services Delivered

Cost of products sold and services delivered were $43.6 million and $37.5 million for the nine months ended September 30, 2014 and 2013, respectively, an increase of $6.1 million, or 16.1%. As a percentage of net sales, cost of products sold and services delivered decreased to 37.0% in the nine months of 2014 compared to 38.4% in the first nine months of 2013. Cost of products sold for our TASER Weapons segment were $34.0 million for the nine months ended September 30, 2014, or 32.4% of TASER Weapons segment sales, compared to $31.5 million for the nine months ended September 30, 2013, or 35.1% of TASER Weapons segment sales. The decrease as a percentage of net sales is primarily derived from increased leverage due to higher sales and higher average selling prices.

Cost of products sold and services delivered for the EVIDENCE.com & Video segment were $9.6 million, an increase of $3.6 million, or 59.6% from the first nine months of 2013. Increased product costs related to the EVIDENCE.com & Video segment related to growing sales in this segment were partially offset by decreased service costs. The decrease in service costs is comprised of cost savings due to the full depreciation of the capitalized EVIDENCE.com software development costs as of September 30, 2013 partially offset by increased implementation personnel expenses and cloud storage fees. As a percentage of net sales, cost of products sold and services delivered increased slightly to 76.1% in the first nine months of 2014 from 75.7% in the first nine months of 2013 as a result of increased implementation personnel. There are a number of fixed costs for the EVIDENCE.com & Video segment which, as we generate traction in the business, we expect to remain relatively stable and should allow for lower cost of services delivered as a percentage of service revenue.

Gross Margin

Gross margin was $74.1 million and $60.3 million for the nine months ended September 30, 2014 and 2013, respectively, an increase of $13.8 million, or 23.0%. Our gross margin as a percent of sales increased to 63.0% for the first nine months of 2014 compared to 61.6% for the first nine months of 2013, a result of the factors discussed above under Costs of products sold and services delivered as well as leverage in overhead expense from increased sales, increased sales prices and lower cloud storage costs. In the fourth quarter of 2013, we introduced a new pricing program reducing the price of the AXON flex cameras and separately pricing the EVIDENCE.com service. In previous quarters, the cameras and service were primarily sold together with one price for both. We believe lowering the price of the cameras and offering separately-priced EVIDENCE.com SaaS contracts at various levels of functionality promotes pricing transparency for our customers. As a result, the gross margins in the EVIDENCE.com & Video segment are expected to be lower in the near-term as the service portion is deferred and recognized over the contract term. The AXON flex and the AXON body are currently being sold at low gross margins in an effort to continue to accelerate the Company’s traction in the market.

Sales, General and Administrative Expenses

For the nine months ended September 30, 2014 and 2013, sales, general and administrative expenses (“SG&A”) were comprised of the following (dollars in thousands):

 

     Nine Months Ended September 30,  
     2014     2013     $
Change
    %
Change
 

Salaries, benefits and bonus

   $ 12,815      $ 10,674      $ 2,141        20.1

Professional, accounting and legal fees and litigation expenses *

     7,282        8,119        (837     (10.3

Office expenses

     3,218        3,164        54        1.7   

Travel and meals

     3,354        2,480        874        35.2   

Stock-based compensation

     2,598        2,293        305        13.3   

Consulting and lobbying

     2,423        1,608        815        50.7   

Depreciation and amortization

     937        930        7        0.8   

Sales and marketing *

     5,293        3,657        1,636        44.7   

Liability insurance

     950        1,490        (540     (36.2

Other

     864        483        381        78.9   
  

 

 

   

 

 

   

 

 

   

Total

   $ 39,734      $ 34,898      $ 4,836        13.9   
  

 

 

   

 

 

   

 

 

   

Sales, general and administrative as a % of net sales

     33.8     35.7    

 

* Sales and marketing, and Professional, accounting and legal fees and litigation expenses are presented excluding salaries, benefits and stock compensation for those departments. Compensation related expenses for those areas are captured in the “Salaries, benefits and bonus” and “Stock-based compensation” lines.

 

28


Table of Contents

SG&A expenses were $39.7 million and $34.9 million for the nine months ended September 30, 2014 and 2013, respectively, an increase of $4.8 million, or 13.9%. As a percentage of net sales, SG&A expenses decreased to 33.8% for the first nine months of 2014 compared to 35.7% for the first nine months of 2013.

Within the TASER Weapons segment, SG&A increased $1.6 million, or 5.2%, to $32.2 million from $30.6 million in the first nine months of 2013. Salaries, benefits and bonus and stock compensation in the TASER Weapons segment increased approximately $1.1 million in the first nine months of 2014 compared to the prior year partially due to increased international, telesales and support sales staff. Incremental administrative functions were also added over the year in order to support the growing business. The increase in personnel expense was partially offset by a decrease in sales and marketing expenses of approximately $0.5 million compared to the prior year due to the timing of the International Association of Chiefs of Police conference.

Within the EVIDENCE.com & Video segment, SG&A increased $3.2 million, or 75.8%, to $7.5 million in the first nine months of 2014 in comparison to the prior year. Salaries, benefits and bonus and stock compensation in the EVIDENCE.com & Video segment increased $1.3 million primarily as a result of the Company doubling its video salesforce and hiring incremental functions such as professional services, public relations and telesales. Sales and marketing expenses in the EVIDENCE.com & Video segment also increased approximately $0.9 million in comparison to the same period in 2013 as a result of TASER-hosted Technology Summits to promote customer awareness about cloud technology as well as EVIDENCE.com promotions and advertising efforts during the first nine months of 2014. Also included in sales and marketing expenses is increased commissions expense of approximately $0.5 million as a result of increased sales. We believe these increases in marketing activities will increase customer awareness of the benefits of EVIDENCE.com and ultimately lead to sales growth in future periods.

The Company expects to see increased SG&A in the fourth quarter due to the timing of the International Association of Chiefs of Police conference, which will occur in the fourth quarter of 2014. The Company also expects higher SG&A expenses for the fourth quarter 2014 and into 2015 as the Company continues to invest and grow the infrastructure necessary to achieve its initiatives of increasing revenues internationally and in the EVIDENCE.com & Video segment.

Research and Development Expenses

Research and development expenses were $10.8 million for the nine months ended September 30, 2014 an increase of $4.4 million or 67.9% over the same period in the prior year. As a percentage of net sales, R&D expense increased to 9.2% in the first nine months of 2014 in comparison to 6.6% in the first nine months of 2013. Research and development expense increased primarily due to additional personnel expense related to EVIDENCE.com & Video segment development initiatives. In the TASER Weapons segment, R&D expenses decreased $0.5 million to $2.7 million in comparison to the same period in the previous year as resources were shifted to developing the next generation products and features for our EVIDENCE.com & Video segment.

The Company continues to expect increased expenses in R&D in the fourth quarter of 2014 and into 2015 as it adds new functionality and new capabilities to the EVIDENCE.com platform.

Provision for Income Taxes

The provision for income taxes was $8.7 million for the nine months ended September 30, 2014, which was an effective tax rate of 36.9 %. Our estimated full year effective tax rate for 2014, before discrete period adjustments, is approximately 37.6%, which is above the statutory rate due to the impact of state taxes and non-deductible expenses for items such as ISO stock option expense, meals and entertainment and lobbying fees, but also reduced by the domestic production activities deduction, the net effects of which makes our projected annual net income for tax purposes higher than our book pre-tax income.

Net Income

Our net income increased to $14.8 million, or $0.27 per diluted share, for the first nine months of 2014 compared to net income of $12.9 million, or $0.24 per diluted share, for the first nine months of 2013.

 

29


Table of Contents

Liquidity and Capital Resources

Summary

As of September 30, 2014, we had $38.6 million in cash and cash equivalents, a decrease of $3.7 million from the end of 2013. Our cash generated by operating activities of $22.6 million, was more than offset by investment purchases of $23.6 million and repurchases of the Company’s common stock of $22.4 million during the first nine months of 2014.

Cash Flows

The following table summarizes our cash flows from operating, investing and financing activities for the nine months ended September 30, 2014 and 2013 (dollars in thousands):

 

     Nine Months Ended September 30,  
     2014     2013  

Operating activities

   $ 22,638      $ 23,087   

Investing activities

     (17,126     (13,236

Financing activities

     (9,284     (10,969

Effect of exchange rate changes on cash and cash equivalents

     116        (3
  

 

 

   

 

 

 

Decrease in cash and cash equivalents

   $ (3,656   $ (1,121
  

 

 

   

 

 

 

Operating activities

Net cash provided by operating activities in the first nine months of 2014 of $22.6 million was primarily driven by $14.8 million of net income for the period, adjusted for the net add-back of non-cash expenses of $11.4 million, including depreciation and amortization expense of $3.4 million, deferred income taxes of $9.9 million and stock-based compensation expense of $4.1 million, offset by a $5.8 million reduction related to excess tax benefit from stock-based compensation. Cash from operating activities reflects a net decrease of $3.6 million related to the net change in assets and liabilities. The net decrease in operating cash was primarily driven by an increase in accounts and notes receivable of $4.8 million, increased inventory of $5.0 million, an increase in prepaid expenses and other assets of $1.1 million, and a reduction of accounts payable and accrued liabilities of $1.7 million. The increase in accounts and notes receivable is attributable to increased invoiced sales. The increase in inventory is due to normal timing fluctuations and anticipated sales. Offsetting these reductions to operating cash inflows was an increase to operating cash flow of $9.8 million resulting from an increased balance of deferred revenue. The increase in deferred revenue primarily related to approximately $4.4 million from growing warranty sales, $2.8 million from increased EVIDENCE.com sales, and $2.6 million in increased TASER Assurance Program sales.

Net cash provided by operating activities in the first nine months of 2013 of $23.1 million was primarily driven by $12.9 million of net income for the period, adjusted for the net add-back of non-cash expenses of $9.5 million, including depreciation and amortization expense of $4.0 million, deferred income taxes of $5.2 million and stock-based compensation expense of $2.9 million, offset by a $4.1 million reduction related to excess tax benefit from stock-based activities. Cash from operating activities during the 2013 period reflects a net increase of $0.8 million related to the net change in assets and liabilities. Increases in notes and accounts receivables, prepaid and other assets and inventory resulted in reductions to operating cash flows of $2.0 million, $2.2 million and $1.6 million, respectively. The increase in accounts receivable was due to increased invoiced sales, and the prepaid and other assets increase is largely due to a $1.6 million increase in prepaid taxes during the 2013 period. The increase in inventory during the 2013 period was due to normal timing fluctuations and anticipated sales. Offsetting these reductions to operating cash inflows was an increase to operating cash flow of $6.5 million resulting from an increased balance of deferred revenue. Of the increase in deferred revenue approximately $3.7 million resulted from growing warranty sales and $2.5 million resulted from increased EVIDENCE.com sales.

Investing activities

We used $17.1 million for investing activities during the first nine months of 2014 primarily as a result of investing cash generated from operating activities. Purchases of investments, net of calls and maturities, were $14.9 million. The Company also invested $2.2 million to purchase property and equipment and intangibles.

Net cash used by investing activities in the first nine months of 2013 was $13.2 million. During the second quarter of 2013 we changed investment managers which, combined with the $23.1 million of operating cash generated during the period and $10.2 million of proceeds from option exercises, enabled higher than previous period investment activity. During the 2013 nine month period, we purchased $18.4 million of investments while receiving proceeds from the call/maturity of investments of $6.6 million. During the 2013 nine month period we purchased $1.4 million of combined property and equipment and intangible assets, which was offset slightly by cash received from the disposal of fixed assets.

 

30


Table of Contents

Financing activities

During the first nine months of 2014, net cash used in financing activities was $9.3 million and was primarily attributable to the repurchase of $22.4 million of our common stock, which was purchased for a weighted average cost of $12.99 per share, offset by $13.2 million of stock option exercises and other share-based payment activities. The weighted average cost includes the average price paid per share of $12.96, plus any applicable administrative costs for the transaction. As of September 30, 2014 the Company has approximately $7.6 million remaining on the repurchase authorization made by TASER’s Board of Directors in May 2014.

During the first nine months of 2013, net cash used by financing activities was approximately $11.0 million primarily attributable to the repurchase of $25.0 million of our common stock, which was purchased for a weighted average cost of $8.20 per share. The weighted average cost includes the average price paid per share of $8.17, plus any applicable administrative costs for the transaction. The repurchase of common stock was made under a previous stock repurchase program.

Liquidity and Capital Resources

Our most significant sources of liquidity continue to be funds generated by operating activities and available cash and cash equivalents. We believe funds generated from our expected results of operations, as well as available cash and cash equivalents, will be sufficient to finance our operations and strategic initiatives for the remainder of 2014. In addition, our $10.0 million revolving credit facility is available for additional working capital needs or investment opportunities. Under the terms of the line of credit, available borrowings are reduced by outstanding letters of credit. As of September 30, 2014, we had letters of credit outstanding of approximately $47,000. The line is secured by our accounts receivable and inventory, and bears interest at varying rates currently LIBOR plus 1.5% to prime. The facility matures on June 30, 2015. There can be no assurance that we will continue to generate cash flows at or above current levels or that we will be able to maintain our ability to borrow under our revolving credit facility. At September 30, 2014 and December 31, 2013, there were no borrowings under the line.

Our agreement with the bank requires us to comply with certain financial and other covenants including maintenance of minimum tangible net worth and a fixed charge coverage ratio. The ratio of total liabilities to tangible net worth can be no greater than 1:1, and the fixed charge coverage ratio can be no less than 1.25:1, based upon a trailing twelve-month period. At September 30, 2014, the Company’s tangible net worth ratio was 0.40:1 and its fixed charge coverage ratio was 2.86:1. Accordingly, the Company was in compliance with these covenants.

Based on our strong balance sheet and the fact that we had only $0.1 million in long-term debt as a capital lease obligation at September 30, 2014, we believe financing will be available, both through our existing credit line and possible additional financing. However, there is no assurance that such funding will be available on terms acceptable to us, or at all, if required.

Off Balance Sheet Arrangements

We had no off balance sheet arrangements as of September 30, 2014 or December 31, 2013.

Critical Accounting Estimates

We have identified the following accounting estimates as critical to our business operations and the understanding of our results of operations. The preparation of this Quarterly Report on Form 10-Q requires us to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent liabilities at the date of our unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. While we don’t believe that a change in these estimates is reasonably likely, there can be no assurance that our actual results will not differ from these estimates. The effect of these policies on our business operations is discussed below.

 

31


Table of Contents

Product Warranties

The Company warrants its CEWs, StrikeLight, AXON cameras and Evidence Transfer Managers (“ETM”) from manufacturing defects on a limited basis for a period of one year after purchase and, thereafter, will replace any defective unit for a fee. Estimated costs for our standard warranty are charged to cost of products sold and services delivered when revenue is recorded for the related product. We estimate future warranty costs based on historical data related to returns and warranty costs on a quarterly basis and apply this rate to current product anticipated returns from our customers. We have also historically increased our reserve amount if we become aware of a component failure that could result in larger than anticipated returns from our customers. The accrued warranty liability expense is reviewed quarterly to evaluate whether it sufficiently reflects the remaining warranty obligations based on the anticipated expenditures over the balance of the warranty obligation period, and adjustments are made when actual warranty claim experience differs from estimates. As of September 30, 2014 and December 31, 2013, our reserve for warranty costs was $0.8 million and $1.0 million, respectively. The nine months ended September 30, 2014, include additional expense due to a change in estimate regarding the Company’s first generation ETM as a result of an updated version launched in the first quarter.

Revenue related to separately-priced extended warranties is recorded as deferred revenue and subsequently recognized in net sales on a straight-line basis over the delivery period. Costs related to extended warranties are charged to cost of products sold and services delivered when incurred.

Inventory

Inventories are stated at the lower of cost or market, with cost determined using the weighted average cost of raw materials, which approximates the first-in, first-out (“FIFO”) method, and an allocation of manufacturing labor and overhead costs. The allocation of manufacturing labor and overhead costs includes management’s judgments of what constitutes normal capacity of our production facilities and a determination of what costs are considered to be abnormal fixed production costs, which are expensed as current period charges. Provisions are made to reduce potentially excess, obsolete or slow-moving inventories to their net realizable value. These provisions are based on our best estimates after considering historical demand, projected future demand, inventory purchase commitments, industry and market trends and conditions and other factors. Our reserve for excess and obsolete inventory was $0.7 million and $1.0 million at September 30, 2014 and December 31, 2013, respectively. In the event that actual excess, obsolete or slow-moving inventories differ from these estimates, changes to inventory reserves may be necessary.

Revenue Recognition, Deferred Revenue and Accounts and Notes Receivable

We derive our revenue from two primary sources: (1) the sale of physical products, including our CEWs, AXON cameras, corresponding extended warranties, and related accessories such as cartridges and batteries, and (2) subscription to our EVIDENCE.com digital evidence management SaaS (including data storage fees and other ancillary services), which includes varying levels of support. To a lesser extent, we also recognize training and other revenue. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, title has transferred, the price is fixed and collectability is reasonably assured. Extended warranty revenue, SaaS revenue and related data storage revenue are recognized ratably over the term of the contract beginning on the commencement date of each contract.

Revenue arrangements with multiple deliverables are divided into separate units and revenue is allocated using the relative selling price method based upon vendor-specific objective evidence of selling price or third-party evidence of the selling prices if vendor-specific objective evidence of selling prices does not exist. If neither vendor-specific objective evidence nor third-party evidence exists, management uses its best estimate of selling price.

EVIDENCE.com and AXON cameras are sold separately, but in most instances are sold together. In these instances, customers typically purchase and pay for the equipment and one year of EVIDENCE.com in advance. Additional years of service are generally billed annually over a specified service term, which has typically ranged from one to five years. AXON equipment represents a deliverable that is provided to the customer at the time of sale, while EVIDENCE.com services are provided over the specified term of the contract. The Company recognizes revenue for the AXON equipment at the time of the sale consistent with the discussion of multiple deliverable arrangements above. Revenue for EVIDENCE.com is deferred at the time of the sale and recognized over the service period. In certain circumstances, not all requirements are met for the recognition of revenue relative to equipment sold in conjunction with EVIDENCE.com at the time the equipment is provided to customers. In such circumstances, based on limitations associated with the arrangement consideration, the revenue may be recognized ratably over the specified term of the contract, or when all conditions for revenue recognition are met, if sooner.

Deferred revenue consists of billings and/or payments received in advance related to products and services for which the criteria for revenue recognition have not yet been met. Deferred revenue that will be recognized during the succeeding twelve month period is recorded as current deferred revenue and the remaining portion is recorded as long-term. Deferred revenue does not include future revenue from multi-year contracts for which no invoice has yet been created. We generally bill customers in annual installments.

Sales are typically made on credit and we generally do not require collateral. We perform ongoing credit evaluations of our customers’ financial condition and maintain an allowance for estimated potential losses. Uncollectible accounts are written off when deemed uncollectible, and accounts and notes receivable are presented net of an allowance for doubtful accounts. This allowance represents our best estimate and is based on our judgment after considering a number of factors including third-party credit reports, actual payment history, customer-specific financial information and broader market and economic trends and conditions. In the event that actual uncollectible amounts differ from our estimates, additional expense could be necessary.

 

32


Table of Contents

Valuation of Goodwill, Intangibles and Long-lived Assets

In the fourth quarter of 2013, we recorded goodwill related to the Familiar business acquisition. The recoverability of the goodwill is evaluated and tested for impairment at least annually during the fourth quarter or more often, if and when circumstances indicate that goodwill may not be recoverable. Finite-lived intangible assets and other long-lived assets are amortized over their useful lives. We evaluate whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and intangible assets may warrant revision or that the remaining balance of these assets, including intangible assets with indefinite lives, may not be recoverable.

Circumstances that might indicate long-lived assets might not be recoverable could include, but are not limited to, a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way our products are branded and marketed. When performing a review for recoverability, we estimate the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of the impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair value computed using discounted cash flows.

Income Taxes

We recognize federal, state and foreign current tax liabilities or assets based on our estimate of taxes payable or refundable in the current fiscal year by tax jurisdiction. We also recognize federal, state and foreign deferred tax assets or liabilities, as appropriate, for our estimate of future tax effects attributable to temporary differences and carry forwards.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such positions are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Management must also assess whether uncertain tax positions as filed could result in a liability for possible interest and penalties if any. We have completed research and development tax credit studies which identified approximately $10.4 million in tax credits for Federal, Arizona and California income tax purposes related to the 2003 through 2014 tax years. Management determined that it was more likely than not that the full benefit of the research and development tax credit would not be sustained on examination and accordingly, has established a cumulative liability for unrecognized tax benefits of $3.2 million as of September 30, 2014. In addition, the Company established a $0.1 million liability related to uncertain tax positions for certain state income tax liabilities, for a total unrecognized tax benefit of $3.3 million. As of September 30, 2014, management does not expect the amount of the unrecognized tax benefit liability to increase or decrease significantly within the next 12 months. Should the unrecognized tax benefit of $3.3 million be recognized, the Company’s effective tax rate would be favorably impacted. Approximately, $1.9 million of the unrecognized tax benefits associated with research and development credits has been netted against the research and development credit deferred tax asset. Our estimates are based on the information available to us at the time we prepare the income tax provisions. Our income tax returns are subject to audit by federal, state, and local governments, generally years after the returns are filed. These returns could be subject to material adjustments or differing interpretations of the tax laws.

Our calculation of current and deferred tax assets and liabilities is based on certain estimates and judgments and involves dealing with uncertainties in the application of complex tax laws. Our estimates of current and deferred tax assets and liabilities may change based, in part, on added certainty or finality to an anticipated outcome, changes in accounting or tax laws in the United States and overseas, or changes in other facts or circumstances. In addition, we recognize liabilities for potential United States tax contingencies based on our estimate of whether, and the extent to which, additional taxes may be due. If we determine that payment of these amounts is unnecessary, or if the recorded tax liability is less than our current assessment, we may be required to recognize an income tax benefit, or additional income tax expense, respectively, in our consolidated financial statements.

In preparing the Company’s condensed consolidated financial statements, management assesses the likelihood that its deferred tax assets will be realized from future taxable income. In evaluating the Company’s ability to recover its deferred income tax assets, management considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction by jurisdiction basis. A valuation allowance is established if it is determined that it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Management exercises significant judgment in determining its provisions for income taxes, its deferred tax assets and liabilities and its future taxable income for purposes of assessing its ability to utilize any future tax benefit from its deferred tax assets. Management has determined that it is more likely than not that future sales and profitability will allow for the utilization of the deferred tax assets. However, the deferred tax asset could be reduced or the valuation allowance could be changed in the near-term if estimates of future taxable income during the carry forward period change.

 

33


Table of Contents

Although management believes that its tax estimates are reasonable, the ultimate tax determination involves significant judgments that could become subject to audit by tax authorities in the ordinary course of business. As of September 30, 2014, the Company would need to generate approximately $33.7 million of pre-tax book income in order to realize the net deferred tax assets for which a benefit has been recorded. This estimate considers the reversal of approximately $6.0 million of gross deferred tax liabilities, $2.3 million tax-effected. We also have gross deferred tax assets of approximately $0.8 million, $0.1 million tax-effected, related to state NOLs which expire at various dates between 2016 and 2031. We anticipate the Company’s future income to continue to trend upward from our 2014 results, with sufficient pre-tax book income to realize our deferred tax assets. As such, we have not recorded a valuation allowance on our deferred tax assets.

Stock-based Compensation

We have historically granted stock-based compensation for various equity owners and key employees as a means of attracting and retaining quality personnel. We have utilized restricted stock awards, restricted stock units and stock options; however, no stock options were issued during 2013 or the first nine months of 2014. The fair value of restricted stock units is estimated as the closing price of our common stock on the date of grant. We estimate the fair value of granted stock options by using the Black-Scholes-Merton option pricing model, which requires the input of highly subjective assumptions. These assumptions include estimating the length of time employees will retain their stock options before exercising them (expected term), the estimated volatility of our common stock price over the expected term and the number of options that will ultimately not vest (forfeitures). The expense for both restricted stock units and stock options is recorded over the life of the grant, net of forfeitures.

We have granted a total of approximately 1.6 million performance-based awards (options and restricted stock awards and units) of which approximately 0.6 million are outstanding as of September 30, 2014, the vesting of which is contingent upon the achievement of certain performance criteria including the successful development and market acceptance of future product introductions as well as our future sales targets and operating performance. These awards will vest and compensation expense will be recognized based on management’s best estimate of the probability of the performance criteria being satisfied using the most currently available projections of future product adoption and operating performance, adjusted at each balance sheet date. Changes in the subjective and probability-based assumptions can materially affect the estimate of fair value of stock-based compensation and consequently, the related amount recognized on our statements of operations.

Contingencies and Accrued Litigation Expense

We are subject to the possibility of various loss contingencies including product-related litigation, arising in the ordinary course of business. We consider the likelihood of loss or impairment of an asset or the incurrence of a liability, as well as our ability to reasonably estimate the amount of loss in determining loss contingencies. An estimated loss contingency is accrued when it is probable that an asset has been impaired or a liability has been incurred and the amount of loss can be reasonably estimated. We regularly evaluate current information available to us to determine whether such accruals should be adjusted and whether new accruals are required. Refer to Note 10 to our condensed consolidated financial statements for further discussion.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk

We typically invest in a limited number of financial instruments, consisting principally of investments in money market accounts, certificates of deposit and corporate and municipal bonds with a typical long-term debt rating of “AA” or better by any nationally recognized statistical rating organization, denominated in United States dollars. All of our investments are treated as “held-to-maturity.” Investments in fixed-rate interest-earning instruments carry a degree of interest rate risk as their market value may be adversely impacted due to a rise in interest rates. As a result, we may suffer losses in principal if we sell securities that have declined in market value due to changes in interest rates. However, because we classify our debt securities as “held-to-maturity” based on our intent and ability to hold these instruments to maturity, no gains or losses are recognized due to changes in interest rates. These securities are reported at amortized cost. As of September 30, 2014, we estimate that a 10 basis point increase or decrease in interest rates would result in a change in annual interest income of less than $0.1 million.

Additionally, we have access to a line of credit borrowing facility which bears interest at varying rates, currently at LIBOR plus 1.5% to prime. At September 30, 2014, there was no amount outstanding under the line of credit and the available borrowing under the line of credit was $9.95 million. We have not borrowed any funds under the line of credit since its inception; however; should we need to do so in the future, such borrowings could be subject to adverse or favorable changes in the underlying interest rate.

Exchange Rate Risk

Our results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates, particularly changes in the Euro related to transactions by TASER Europe. To date, we have not engaged in any currency hedging activities, although we may do so in the future. Fluctuations in currency exchange rates could harm our business in the future.

 

34


Table of Contents

The majority of our sales to international customers is transacted in U.S. dollars and therefore, is not subject to exchange rate fluctuations. However, the cost of our products to our customers increases when the U.S. dollar strengthens against their local currency and the Company may have more sales and expenses denominated in foreign currencies in 2014 which would increase its foreign exchange rate risk.

Item 4. Controls and Procedures

Evaluation of disclosure controls and procedures

Our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2014 to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in internal control over financial reporting

There was no change in our internal control over financial reporting during the fiscal quarter ended September 30, 2014, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

The discussion of legal proceedings in Note 10 to the unaudited condensed consolidated financial statements included in PART I, ITEM 1 of this Form 10-Q is incorporated by reference herein.

Item 1A. Risk Factors

In addition to the other information set forth in this report, you should carefully consider the factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2013, under the heading “Risk Factors,” which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially, adversely affect our business, financial condition and/or operating results.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In May 2014, the Company announced that TASER’s Board of Directors authorized a stock repurchase program to acquire up to $30.0 million of the Company’s outstanding common stock subject to stock market conditions and corporate considerations. During the quarter ended September 30, 2014, the Company purchased approximately 0.2 million common shares under this program for a total cost of approximately $2.9 million, or a weighted average cost of $11.94 per share. The weighted average cost includes the average price paid per share of $11.91, plus any applicable administrative costs for the transaction. During the five month period from inception of the repurchase program through September 30, 2014, the Company purchased approximately 1.7 million common shares under this program for a total cost of approximately $22.4 million, or a weighted average cost of $12.99 per share. The weighted average cost includes the average price paid per share of $12.96, plus any applicable administrative costs for the transaction. The table below sets forth information regarding repurchases of our common stock by us during the quarter ended September 30, 2014 (in thousands, except per share data):

 

                   Total Number of Shares      Approximate Dollar  
                   Purchased as Part of      Value of Shares that May  
     Total Number of      Average Price      Publicly Announced      Yet be Purchased Under  

Period

   Shares Purchased      Paid per Share      Plans or Programs      the Plans or Programs  

July 1 – 31, 2014

     37       $ 12.99         37       $ 9,967   

Aug 1 – 31, 2014

     205         11.72         205         7,557   

Sept 1 – 30, 2014

     —           —           —           7,557   
  

 

 

       

 

 

    

Total

     242         11.91         242      
  

 

 

       

 

 

    

 

35


Table of Contents

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.

 

36


Table of Contents

Item 6. Exhibits

 

31.1    Principal Executive Officer Certification pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
31.2    Principal Financial Officer Certification pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
32    Principal Executive Officer and Principal Financial Officer Certifications pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101    XBRL Instance Document
101    XBRL Taxonomy Extension Schema Document
101    XBRL Taxonomy Calculation Linkbase Document
101    XBRL Taxonomy Label Linkbase Document
101    XBRL Taxonomy Presentation Linkbase Document
101    XBRL Taxonomy Definition Linkbase Document

 

37


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    TASER International, Inc.
Date: November 04, 2014    

/s/ Patrick W. Smith

    Patrick W. Smith
   

Chief Executive Officer

(Principal Executive Officer)

Date: November 04, 2014    

/s/ Daniel M. Behrendt

    Daniel M. Behrendt
   

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

38


Table of Contents

Index to Exhibits

Exhibits:

 

31.1    Principal Executive Officer Certification pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
31.2    Principal Financial Officer Certification pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
32    Principal Executive Officer and Principal Financial Officer Certifications pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101    XBRL Instance Document
101    XBRL Taxonomy Extension Schema Document
101    XBRL Taxonomy Calculation Linkbase Document
101    XBRL Taxonomy Label Linkbase Document
101

101

  

XBRL Taxonomy Presentation Linkbase Document

XBRL Taxonomy Definition Linkbase Document

 

39